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At a Glance
What is the current scientific knowledge on this subject?
Cumulative oral corticosteroid treatment for asthma is associated with costly and burdensome 
side effects and comorbidities. ‘OCS stewardship’ is advocated to protect patients from 
inappropriate OCS use and its consequences. The advent of effective OCS-sparing biological 
therapies also fosters new opportunities for tapering. Currently, evidence-based guidelines for 
OCS use, tapering, and associated comorbidity screening in asthma are lacking.
What does this study add to the field?
In the absence of clinical data to develop evidence-based guidelines, this modified Delphi 
consensus study brought together experts with relevant knowledge and clinical experience to 
generate a high-quality expert consensus statement on OCS use and tapering. The 
recommendations thus generated support minimizing OCS use in as much as possible. A 
cumulative yearly dose of 0.5 or 1g prednisolone equivalents would be indicative of poor 
asthma control. They also provide a first step towards development of an OCS tapering 
algorithm, as well as a minimum OCS adverse event screening list. Little consensus was 
achieved concerning the assessment and management of adrenal insufficiency, supporting a 
need for future related research in this specific domain. Finally, the experts strongly support 
shared decision making during OCS tapering.
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Abstract
Rationale: There is a need to minimize oral corticosteroid use in patients with asthma to 
prevent their costly and burdensome adverse effects. Current guidelines do not provide 
recommendations for oral corticosteroid tapering in patients with asthma.
Objectives: To develop expert consensus on oral corticosteroid tapering among international 
experts. 
Methods: A modified Delphi method was used to develop expert consensus statements 
relating to oral corticosteroid use, tapering, adverse effects, adrenal insufficiency, and 
patient-physician shared decision-making. Initial statements proposed by experts were 
categorized, filtered for repetition, and presented back to experts over three ranking rounds to 
obtain consensus (≥70% agreement).
Measurements and Main Results: 131 international experts participated in the study and 
296 statements were ranked. Numerous recommendations and guidance regarding appropriate 
oral corticosteroid use were established. Experts agreed that oral corticosteroid tapering 
should be attempted in all patients with asthma receiving maintenance oral corticosteroid 
therapy, with personalization of tapering rhythm and speed. The importance of recognizing 
individual adverse effects was also established; however, a unified approach to the 
assessment of adrenal insufficiency was not reached. Shared decision-making was considered 
an important goal during the tapering process.
Conclusion: In this Delphi study expert consensus statements were generated on oral 
corticosteroid use, tapering, adverse effects screening, and shared decision-making, which 
may be used to inform clinical practice. Areas of non-consensus were identified, highlighting 
uncertainty among the experts around some aspects of oral corticosteroid use in asthma, such 
as adrenal insufficiency, which underscores the need for further research in these domains.
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Keywords (3–5): adrenal insufficiency, adverse effects, shared decision-making, biological 
treatments
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Introduction
Asthma is a chronic inflammatory disease, characterized by reversible airway obstruction and 
airway hyperresponsiveness (1), which affects ~339 million individuals worldwide (2). 
Approximately 5–10% of the overall asthma population have severe asthma (3), defined as 
uncontrolled asthma despite adherence to maximal optimized therapy and treatment of 
contributory factors (4). Severe asthma is associated with greater asthma-related morbidity, 
increased healthcare costs, more frequent exacerbations, and greater oral corticosteroid 
(OCS) use compared with mild/moderate asthma (5–8).
Early use of OCS in emergency department asthma treatment reduces hospital 
admission rates (9), supporting its routine guideline-recommended use for asthma 
exacerbations (4). Indeed, during acute exacerbations OCS have been observed to provide 
rapid benefit (10). Nevertheless, such benefits may be dose- or duration-dependent, and the 
current guidance remains somewhat empirical. Long-term, low-dose OCS add-on therapy is 
restricted to Global Initiative for Asthma (GINA) Step 5 and positioned after trials of other 
more preferential add-on treatments (e.g. tiotropium and biologicals), with consideration of 
side effects (4). However, long-term OCS therapy continues to be widely used in severe 
asthma, with global usage estimated at 20–60% (11).
Recent studies across multiple therapy areas demonstrate that cumulative OCS use 
(including long-term and intermittent use) is associated with a dose- and duration-dependent 
risk of potentially serious adverse effects including osteoporosis, hypertension, diabetes 
mellitus, cataracts, fractures, obesity, and gastrointestinal disorders(6, 11–13). Risk of 
adverse effects is evident at relatively low cumulative and mean daily OCS doses (12). 
Furthermore, long-term OCS use is associated with increased risk of mortality, reduced 
quality of life, and increased healthcare resource utilization and costs (5, 6, 14–16).
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The costly and burdensome adverse effects associated with OCS use have prompted 
international respiratory experts to call for a structured ‘OCS stewardship’ approach to 
protect patients from inappropriate OCS use and its consequences (16, 17). Tapering has been 
strengthened by the availability of effective OCS-sparing biological therapies; however, the 
process should still be approached with caution to prevent symptom recurrence and to avoid 
risking unrecognized adrenal insufficiency (12, 18). Reporting on successful OCS tapering 
protocols is most often indirect (i.e. the tapering algorithm is not the subject of study per se) 
and results in a diverse selection of study-specific algorithms (19–26), whose detail varies 
significantly between published studies. Current recommendations (4, 27) do not provide 
guidance on the choice of OCS tapering protocol or otherwise how to taper. From a clinical 
perspective, the lack of asthma-specific guidelines on OCS tapering and the systematic 
screening of adverse events represents a key barrier to reducing OCS use (16). In the absence 
of clinical data to develop evidence-based guidelines, this modified Delphi consensus study 
aimed to bring together experts with relevant knowledge and clinical experience to generate a 
high-quality expert consensus statement on OCS use and tapering.
Methods
Study Design
An international panel of experts participated in a four-round Delphi study to develop a 
systematic consensus on OCS tapering. The protocol was approved by the Institutional 
Review Board, University Hospital of Montpellier (reference number: 2019 IRB-MTP 04-12) 
and was registered on clinicaltrials.gov (NCT03934801). Surveys were administered 
anonymously to the expert panel using SurveyMonkey online software 
(www.surveymonkey.co.uk). Statistical analyses were performed using the R programming 
environment version 3.6.1 (28).
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Participants and Expert Recruitment
The study steering committee (ERB, AB, GWC, MG, AMG, DP) provided initial 
recommendations of experts (based on their professional/association networks) to be invited 
to enroll in the study and eligible/responding experts were asked to recommend additional 
experts in the field. Pulmonologists/respiratory disease specialists, allergists, 
endocrinologists, pediatricians, rheumatologists, and patient advocacy organization 
representatives were eligible for study enrollment. Clinicians were required to manage 
patients on a weekly basis and have clinical experience in managing disease following OCS 
tapering/withdrawal to ensure a high-level knowledge in OCS management. Patient advocacy 
organization representatives were required to represent an asthma patient advocacy group. 
Experts were excluded if they were currently, or due to be (in the following 12 months) 
employed by, or had ownership in a pharmaceutical company. Participants were encouraged 
to provide complete responses to all survey rounds and reminders were delivered daily. 
Round 1: Expert Demographics and Brainstorming
Participants completed an electronically administered questionnaire to provide demographic 
information, including age, sex, qualifications, practice environment, specialty, years since 
training completion, time spent caring for patients treated with OCS, and number of patients 
seen per year. To initiate the brainstorming process, the questionnaire included open-ended 
questions to generate an initial list of statements pertaining to six categories: appropriate OCS 
use, OCS tapering, addressing adverse effects, adrenal insufficiency, patient-physician shared 
decision-making, and other aspects they felt to be important. Experts were informed that all 
OCS dosages should be expressed as prednisone-equivalent dosages, as reported in GINA 
guidelines (4). Raw statements (which refer to adult patients unless otherwise indicated) were 
categorized, filtered to avoid repetition, and amended for clarity (if necessary) to generate a 
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final list of statements for ranking. The demographics/brainstorming and ranking 
questionnaires are available on the Open Science Framework platform (https://osf.io/wrdbu/).
Rounds 2, 3, and 4: Ranking
The final list of statements was presented to experts for ranking using a pre-defined Likert 
scale ranging from ‘strongly disagree’ (–2 points) to ‘strongly agree’ (+2 points). Experts 
were also asked to select specific responses for treatment duration, threshold values, and 
assessment frequencies. A stopping rule was enforced for a given statement when ≥70% of 
experts indicated ‘agree’ or ‘strongly agree’ (positive consensus), or when ≥70% indicated 
‘disagree’ or ‘strongly disagree’ (negative consensus) during any round. For statements 
requiring a specific response consensus was defined as 70% of experts providing an identical 
response. Items that achieved consensus were not re-presented in subsequent ranking rounds. 
Results
Participants
Of the 363 experts invited to participate in this Delphi study, 169 were enrolled in the expert 
panel and 131 completed at least one of the four survey rounds (Figure 1A). Participant 
attrition rates during the ranking process were low; of the 108 experts who participated in the 
first ranking round, 96 proceeded to complete all three rounds of ranking (Figure 1B). Most 
experts were pulmonologists (73%) or allergists (18%); however, a wide range of specialties 
were represented in the study. Demographics and professional characteristics of the expert 
panel are provided in Table 1.
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Ranking Results
The initial brainstorming survey was completed over a 2-month period (April–May 2019) and 
three rounds of ranking surveys (rounds 2–4) were completed between 31 August and 
26 September 2019. Ninety-one experts provided at least one brainstorming statement and 
1447 statements were generated in total. Raw statements were categorized and filtered to 
avoid repetition resulting in a final list of 296 statements. The following sections summarize 
key points of consensus, but do not cover all 296 items presented to the experts. Full ranking 
results for all 296 statements are available in the online supplement (pp 1–21).
Section 1: Appropriate OCS Use for the Treatment of Asthma
Over 95% of experts agreed or strongly agreed with the following statement: ‘In general, our 
goal should be not to use OCS. When nevertheless required, dose and duration should be 
minimized.’
Short-term OCS use: Positive consensus was reached for five out of six statements 
regarding appropriate short-term OCS use (online supplement p 1; 1.2.a–f). Short-term OCS 
use (<15 days) was deemed appropriate in patients experiencing acute non-resolving or life-
threatening exacerbations and in patients experiencing eosinophilic or allergic exacerbations. 
Experts also agreed that short-term OCS use was appropriate within an asthma management 
plan or to avoid hospitalization. No consensus was reached on whether short-term OCS use 
was appropriate to palliate unavailability of hospitalization services. Experts agreed that 5–7 
days constitutes the usual maximal duration for a short course of OCS for treatment of an 
exacerbation and that the optimal dosage of a short course of OCS should be 0.5 mg/kg/day. 
Items that remained controversial included whether dosages for short courses of OCS for 
treatment of an exacerbation should remain stable and whether the need for individual 
tailoring of OCS dose would render systematic application of ‘ideal’ doses unlikely.
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Maintenance OCS use: Nine statements were proposed regarding appropriate use of 
OCS as a maintenance (long-term) treatment, with five statements reaching consensus (online 
supplement pp 1–2; 1.6.a–i). Maintenance OCS use was considered appropriate in patients 
with severe asthma experiencing inadequate control despite optimization of GINA Step 5 
treatments, or when adverse effects that could not be managed by another treatment presented 
during a tapering attempt. Consensus was also reached on eight of 13 statements 
characterizing an adequate response to long-term OCS use (online supplement pp 2–3; 1.9.a–
m). In situations where OCS maintenance treatment is appropriate, experts considered ≤5 
mg/day to be an acceptable dose (Figure 2).
Maintenance OCS use remained controversial in the context of adrenal insufficiency 
and to reduce overall OCS exposure. There was no consensus on whether maintenance OCS 
use is appropriate based on a patient’s T2 phenotype.
Over 90% of experts agreed or strongly agreed that the annual cumulative OCS dose 
should be monitored as a marker of asthma control. Over 75% of experts selected a threshold 
of 0.5 g or 1 g as the annual cumulative OCS dose indicative of poor control in ranking 
round 3 (Figure 3).
It was agreed that biological therapies are useful OCS-sparing agents, and patients 
should be systematically assessed for suitability for biological therapy. Daily OCS dose may 
represent a reliable marker for the evaluation of biological treatment response (online 
supplement p 5; 1.16.g; 1.17.a–c).
Section 2: OCS Tapering
Two general statements reached positive consensus in the first round of ranking: 1) ‘Tapering 
(down to a minimal efficacious dose or complete weaning, if possible) should be attempted in 
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all asthma patients receiving maintenance OCS therapy, regardless of comorbidities’; 2) 
‘The rhythm and speed of OCS tapering requires individualization for each patient.’
Multiple statements reached positive consensus on when it may be appropriate to 
attempt OCS tapering, and when cautious slow attempts of tapering and complete OCS 
cessation are appropriate (Table 2). Tapering was deemed appropriate in multiple cases 
(online supplement p 5; 2.2.a–f) including: if the intensity or duration of OCS use is a cause 
for concern, if a patient exhibits OCS-related adverse effects or a lack of response to OCS, 
holds a reasonable likelihood of hypothalamic-pituitary-adrenal-axis recovery, or experiences 
improved asthma control following initiation of biological therapy. Tapering was also 
deemed appropriate in patients experiencing asthma control with OCS maintenance therapy 
for a minimum agreed-upon time; however, the duration of the minimum length of time 
remained controversial.
Tapering attempts were deemed inappropriate in patients with eosinophilic 
granulomatosis with polyangiitis or allergic bronchopulmonary aspergillosis that relapses 
during tapering (online supplement p 6; 2.4.b–c). Further statements that remained 
controversial included tapering in patients who demonstrated potentially harmful effects 
during previous tapering attempts and whether tapering should be attempted in patients with 
adrenal insufficiency (online supplement pp 5–6; 2.4.a,d).
Experts agreed that OCS tapering should incorporate some aspect of individualization 
and multiple factors were considered that may influence the rhythm and speed of OCS 
tapering (online supplement p 6; 2.5.a–g); such factors included: duration of previous 
maintenance OCS treatment, history and future risk of adverse effects, and type of adverse 
effect present. Three statements that remained controversial concerned the speed of OCS 
tapering in patients with a fast/slow response to OCS, whether OCS tapering should be 
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guided by biomarkers at each weaning step, and whether the speed of tapering should be 
dependent on the known rapidity of action of the OCS-sparing drug introduced.
Five statements concerning characteristics of an acceptable OCS tapering algorithm 
reached positive consensus, and three statements remained controversial (Table 3). Experts 
agreed that biologicals should play an important role in OCS tapering and that failure to 
achieve a ≥50% OCS dose reduction indicates failure of the biological and may warrant 
switching strategies (online supplement p 9; 2.11.c,e); furthermore, when writing 
prescriptions, the option to reduce dose should be considered (online supplement p 9; 2.12.c). 
Section 3: Addressing OCS-Related Adverse Effects
All five general statements concerning adverse effects reached positive consensus in the first 
round of ranking (online supplement p 9; 3.1.a–e). Experts agreed that patients receiving 
OCS were at greater risk of adverse effects compared with patients receiving no OCS, and 
adverse effects should always be addressed, but should not preclude attempting to taper OCS 
to the lowest possible dose.
Experts reached positive consensus on two of three adverse effect subsets for whom 
OCS tapering should be a priority (online supplement pp 10–11; 3.4.a–c). A positive 
consensus was achieved in the first round of ranking for seven of ten elements that should be 
included in a minimum checklist for adverse effect screening in patients receiving OCS 
therapy, and three statements remained controversial (Table 4).
Section 4: Managing Adrenal Insufficiency
The majority of statements (44/55 [80%]) concerning adrenal insufficiency failed to reach 
consensus following three ranking rounds. Many statements that remained controversial 
concerned the sub-populations in which adrenal insufficiency should be assessed (online 
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supplement pp 13–14; 4.3.a–f, 4.4.a–d). Experts agreed that adrenal insufficiency should be 
assessed in individuals on regular, long-term OCS therapy. Additionally, a positive consensus 
was almost reached (69% agreement) on statements indicating that adrenal insufficiency 
should be assessed in patients exceeding an OCS dose of >2 g per year or >four repeated 
OCS short courses per year.
Experts agreed that adrenal insufficiency is inadequately assessed (online supplement 
p 16; 4.11.a) and should be assessed regularly (online supplement p 121; 4.1.a) and when 
OCS tapering has failed in OCS-treated patients (online supplement p 14; 4.5.b). Experts also 
agreed that signs of adrenal insufficiency should be symptomatically treated as much as 
possible during the tapering process and should not be viewed as a reason to give up on 
tapering altogether (online supplement p 12; 4.1.b). Experts agreed that adrenal insufficiency 
should be assessed using fasting morning cortisol and in case of intermediate results, follow 
up with a (short) tetracosactide/cosyntropin (e.g. Synacthen®) test (online supplement p 15; 
4.9.c). An additional general statement regarding whether hydrocortisone replacement is 
preferred to continued prednisolone almost reached positive consensus, with 65% of experts 
agreeing with the statement and 8% disagreeing; the remaining percentage remained neutral 
on the subject (online supplement p 12; 4.1.c). 
Consensus was reached on the need for the treating respiratory physician to assess for 
adrenal insufficiency in patients with severe asthma, and that management of adrenal 
insufficiency in patients with severe asthma should involve an endocrinologist or a 
multidisciplinary approach (online supplement p 20; 6.1.c,d).
Section 5: Patient-Physician Shared Decision-Making
Experts agreed that shared decision-making should be a systematic practice and self-
management should be limited to individuals with good levels of comprehension (online 
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supplement p 17; 5.1.a,d). Eight statements achieved positive consensus on the importance of 
shared decision-making (online supplement p 17; 5.2.a–h) and 14 statements reached positive 
consensus concerning the content to be included in the shared decision-making process 
(online supplement pp 17–18; 5.3.a–n).
Section 6: Miscellaneous
Experts agreed that primary care physicians prescribing at least three courses of OCS/year to 
a patient should consider specialist referral (online supplement p 20; 6.2.a). Experts also 
achieved positive consensus on 16/17 statements concerning future research of OCS tapering 
(online supplement pp 20-21; 6.3.a–q). The only subject that remained controversial 
concerning future work was the efficacy of internet-provided algorithms for delivering 
symptom-driven OCS tapering guidance to asthma patients.
Discussion
This Delphi study generated expert consensus and recommendations on numerous statements 
concerning appropriate OCS use, OCS tapering, adverse effects, patient-physician shared 
decision-making, and future research domains. Consensus was reached on general statements 
concerning adrenal insufficiency; however, beyond generalities, consensus was not reached. 
Hence, improving the assessment of adrenal insufficiency was one of multiple domains 
identified as requiring future research.
To our knowledge, no existing asthma-specific guidelines are currently available to 
guide OCS tapering in clinical practice. Consensus stated that tapering should be attempted in 
all asthma patients receiving maintenance OCS therapy, regardless of comorbidities; 
however, speed and rhythm of tapering should be individualized. Furthermore, expert 
consensus was reached on characteristics of an acceptable OCS tapering algorithm (Table 3), 
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which constitutes a first step towards the development of OCS tapering algorithms for use in 
clinical practice. These consensuses and related information are summarized in Figure 4.
Successful OCS tapering algorithms have been reported in the past (19–25, 29, 30), but 
vary greatly in content and reporting quality. Currently, the most detailed and recent OCS 
tapering algorithm is being tested in the eagerly awaited PONENTE study (26). Certain 
previous studies also demonstrate that prescribing treatment guided by eosinophil levels can 
improve control, whilst simultaneously resulting in some corticosteroid sparing (31–33). 
Current GINA guidelines suggest OCS dose adjustment may be supported by internet-based 
monitoring of symptom control and exhaled nitric oxide; however, the latter contributed little 
to algorithm decisions, in favor of ACQ scores (34). In the current study, only asthma control 
questionnaires reached positive consensus as a useful tool during OCS tapering. The need for 
laboratory tests or at-home lung function measurements may render many biomarker 
approaches impractical for patients and clinicians. In addition, GINA recommends gradually 
decreasing or stopping OCS in patients with a good response to biological therapies. 
Successful corticosteroid reduction following initiation of biological therapies, using pre-set 
tapering protocols, has been demonstrated in multiple studies (18). However, the latter are 
often short-term in nature with little focus on adrenal function assessments, and the full 
potential of tapering was therefore not achieved/documented. As the use of biological 
therapies increases, studies evaluating OCS tapering regimens on a longer basis, which can 
be personalized based on factors such as baseline OCS dosage and level of asthma control, 
will become increasingly important (e.g. the PONENTE study) (26). The current consensus 
statement provides broader guidance on when and how to taper OCS in patients with asthma 
(Figure 4), regardless of whether a biological therapy has been initiated.
Regarding appropriate OCS use, experts felt that long-term use is not appropriate in 
situations where other treatment options are available. However, if no alternative treatment 
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options are available, experts considered ≤5 mg/day to be an acceptable dose. This threshold 
is considerably lower than the definition in current GINA guidelines, which defines low-dose 
maintenance OCS as ≤7.5 mg/day (4) and may result from the way the question was designed 
to span the range of thresholds mentioned during the brain storming phase of the study. The 
reader should note that non-consensus fractions of experts are willing to use 10 mg/day doses 
and higher, suggesting that there is considerable non-guideline-conforming OCS usage in the 
field, even among experts. The low consensus threshold at 5mg may also reflect the 
increasing importance of biologics in the domain and the resulting opportunities for tapering 
down to the lowest efficacious dose possible or complete cessation. Regardless, the reader 
should also keep in mind that a 5mg/day OCS dose amounts to a cumulative dose exceeding 
1.8 g/year.
In this study, when experts were asked to consider cumulative OCS doses, they voted 
that 0.5 or 1 g/year would be indicative of poor asthma control. This would correspond to 
approximately 3.5-7 months of maintenance treatment at 5 mg/day. A previous study by Price 
et al demonstrated that diabetes associated with OCS use emerged at lifetime cumulative 
systemic corticosteroid exposures of 0.5–<1 g, with most other adverse events emerging at 
1.0 to <2.5 g (12). Furthermore, a 2020 study stated that a yearly cumulative OCS dose above 
1 g should be considered unacceptable in severe asthma and indicates the need for specialist 
referral (35). Even a short term use, which amounts to a median of 20 mg per day for 
approximately 6-days in a large database study, is associated with an increase in sepsis, 
venous thromboembolism, and fracture in the next 30 days (36). These studies highlight the 
need for earlier specialist referral and earlier consideration of OCS-sparing strategies in 
patients receiving OCS.
Biological therapies were a common subject among the experts and the initiation of a 
successful biological therapy was the highest-ranked situation appropriate for initiating OCS 
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tapering (Table 2). The reader should keep in mind that there are other important reasons for 
initiating tapering, such as side effects or non-response (Table 2). Key criteria for success of 
a biological therapy include maintenance of asthma control, reduction in exacerbations, and 
decrease in dose of OCS (27, 37). However, there is no clear guidance on the magnitude of 
OCS reduction that constitutes success or failure of a biological therapy. In this study, 
consensus stated that failure to achieve ≥50% reduction in OCS indicates failure of the 
biological therapy and may warrant a switch in strategy. The guidance provided here will 
support clinical decision-making. 
Items included on the minimal checklist for adverse effect screening (Table 4) have 
been well documented in the literature among individuals receiving OCS. Early detection of 
adverse effects has been shown to be important in the treatment and management of OCS-
related complications; the items on the checklist provide a basis for adverse effect screening 
in clinical practice (6, 11, 12, 38). This checklist further underlines the importance of adverse 
effect prevention measures, including calcium and vitamin D supplementation and 
appropriate prescribing of bisphosphonates for osteoporosis, optimizing ICS dose and 
medication adherence. The latter may additionally allow further reduction in OCS dose.
Previous studies have shown that adrenal insufficiency is common among frequent 
users of OCS following tapering (39); however, lack of clear guidance for clinicians on how 
to manage adrenal insufficiency may hinder OCS reduction in patients with severe asthma 
(16). Experts agreed on the need to regularly assess for adrenal insufficiency, and that fasting 
morning cortisol tests may be used (followed up with a (short) tetracosactide/cosyntropin test 
in case of intermediate results). Experts also highlighted the need for a process to be in place 
for referral to an endocrinologist alongside further research and potential education in this 
domain. The majority of experts agreed use of hydrocortisone replacement therapy is 
preferential to continued prednisolone use to aid the tapering process in the case of adrenal 
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insufficiency; however, consensus was not reached. The lack of consensus on this point is not 
surprising given that the optimal strategy for glucocorticoid replacement in patients with 
adrenal insufficiency remains controversial in the literature. In the UK, hydrocortisone is the 
first-line treatment in management of adrenal insufficiency, followed by prednisolone (40). 
Prednisolone is less expensive and some experts contend it may mimic the circadian rhythm 
more closely than the standard thrice-daily hydrocortisone therapy; however, prednisolone 
may also be associated with increased relative risk of cardiovascular disease (40–42). Results 
of ongoing head-to-head studies will improve understanding regarding this issue (43).
Shared decision-making in OCS tapering was viewed positively by the experts. The 
consensus was that although the OCS-tapering process should be primarily driven by the 
physician, patients should contribute to the decision-making process and be educated on OCS 
use and tapering. Patient’s perceptions are frequently ambivalent towards OCS and how they 
navigated previous tapering attempts should be taken into account. This is in line with 
emerging evidence showing that shared decision-making is becoming more common in 
asthma management and has been shown to improve patient adherence, outcomes, and 
satisfaction with care (44). Shared decision making tools/platforms to facilitate this process 
(e.g. 43, 44) require further development and validation for general asthma populations.
The strengths of this study include participation of 131 experts across a range of 
specialisms, ensuring that a wide breadth of knowledge and relevant expertise was 
represented among the expert panel. Results from this study also benefit from the anonymity 
of expert responses, alongside a clear, a priori definition of consensus criteria and controlled 
feedback. Importantly, a lack of participant attrition was observed throughout all three 
ranking rounds, increasing the validity of the consensus by avoiding suppression of minority 
opinions and minimizing potential for bias (47). A limitation of the study was the large 
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number of raw statements that needed to be reduced and summarized; therefore, statements 
presented to experts were not fully representative of all the raw statements.
This Delphi consensus study provides expert consensus statements around OCS use and 
tapering, which may be used to inform clinical practice and optimize management of patients 
with severe asthma. The recommendations also provide a first step towards development of 
an OCS tapering algorithm and support the ongoing OCS stewardship effort by international 
respiratory experts to reduce the harm from inappropriate OCS use and its consequences. 
While consensus was generated on numerous statements, many remained controversial, 
highlighting the existing uncertainty, even among international experts, around certain 
aspects of OCS use in asthma, such as assessment and management of adrenal insufficiency. 
These findings underscore the need for further research to inform clinical practice and drive 
future evidence-based guideline development.
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Figure legends
Figure 1. (A) Study flow diagram. (B) Expert participation in three statement-ranking rounds.
A
B
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Figure 2. Percentage agreement among experts on acceptable doses for maintenance OCS 
treatment. OCS = oral corticosteroid.
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Figure 3. Percentage agreement among experts for threshold options indicating a yearly 
cumulative OCS dose that is suggestive of poor asthma control. NA = not applicable; 
OCS = oral corticosteroid.
Page 32 of 71
 AJRCCM Articles in Press. Published October 28, 2020 as 10.1164/rccm.202007-2721OC 
 Copyright © 2020 by the American Thoracic Society 
Figure 4. Graphic summary of consensus information on oral corticosteroid tapering.
*Adrenal insufficiency should be regularly assessed using fasting morning cortisol. In case of 
intermediate results, follow up with a (short) tetracosactide/cosyntropin test. Adrenal 
insufficiency management should be multidisciplinary, involving an endocrinologist.
**Comorbidity screening should include at least the following: glycemic control, bone 
density, blood pressure, cataracts and glaucoma, weight change, fracture risk score and 
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growth in pediatric populations. However, no consensus was achieved concerning the 
periodicity of comorbidity screening measures.
ABPA = allergic bronchopulmonary aspergillosis; ACQ = asthma control questionnaire; 
EGPA = eosinophilic granulomatosis with polyangiitis; HPA = hypothalamic–pituitary–
adrenal axis; OCS = oral corticosteroids.
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Age 131 50.6 ± 9.64
Sex (female) 35/131 26.72%
Academic qualification 131




University hospital 117 89.31%
Private practice 11 8.40%
Academic environment 37 28.24%
Patient care environment 13 9.92%
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Patient advocacy organization representatives 2 1.53%
Pulmonologist/Respiratory disease specialist 95 72.52%
Rheumatologist 1 0.76%
Years since completion of training 131 19 (10 to 27)
Approximate % of work spent in caring for patients treated 
with OCS
131 15 (5 to 30)
How often tapering is attempted in OCS patients 131




Participation in studies with aim of OCS tapering 80 61.07%
Concerning OCS
Protocols, no. 131 2 (1 to 4)
Scientific articles, no. 131 2 (0 to 5)
Patients seen per year, no. 131 50 (25 to 100)
Concerning asthma
Protocols, no. 131 10 (4 to 20)
Scientific articles, no. 131 30 (6 to 60)
Patients seen per year, no. 131 300 (100 to 500)
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In all
Protocols, no. 131 20 (10 to 40)
Scientific articles, no. 131 67 (25 to 132)
Patients seen per year, no. 131 600 (400 to 1200)
Definition of abbreviations: NA = not applicable; OCS = oral corticosteroid.
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Proceeding towards a tapering attempt is particularly appropriate when:
Biological treatment has been initiated and results in asthma control 0.00 0.95 0.95 25.71 72.38 1.70
The patient does not appear to respond to OCS treatment 0.00 0.95 0.95 35.24 62.86 1.60
A patient exhibits symptoms/comorbidities likely linked to OCS 0.00 1.90 2.86 41.90 53.33 1.47
Patients on maintenance OCS have gained control (for a minimum 
agreed-upon time)
0.00 0.00 3.81 59.05 37.14 1.33
The intensity or duration of OCS treatment gives reason for concern 0.00 0.00 3.81 59.05 37.14 1.33
There is reasonable likelihood of hypothalamic-pituitary-adrenal axis 
recovery
0.00 1.90 11.43 54.29 32.38 1.17
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Tapering should not be attempted in patients who:
Have EGPA that relapses during tapering (and no other changes can 
be proposed)
0.95 3.81 12.38 66.67 16.19 0.93
Have ABPA that relapses during tapering (and no other changes can 
be proposed)
0.00 9.52 19.05 61.90 9.52 0.71
Cautious slow tapering is particularly appropriate for patients who:
Have had life-threatening attacks 0.95 3.81 3.81 60.00 31.43 1.17
Have been dependent on systemic steroids for an extended period (e.g. 
6 months or more)
0.00 2.86 6.67 63.81 26.67 1.14
Have comorbidities that respond to OCS 0.00 3.81 9.52 70.48 16.19 0.99
Complete OCS cessation (weaning) can be implemented:
Following a short course of OCS treatment that lasted for 5–7 days 0.95 1.90 1.90 44.76 50.48 1.42
Following a short course of OCS treatment if patients are on inhaled 
anti-inflammatory therapy
1.90 1.90 2.86 48.57 44.76 1.32
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When a sparing strategy has been initiated 0.95 2.86 14.29 54.29 27.62 1.05
When there is no evidence of adrenal insufficiency 0.95 6.67 13.33 59.05 20.00 0.90
When the patient has agreed to cessation 1.90 4.76 20.00 50.48 22.86 0.88
When there is no evidence of EGPA or ABPA 0.00 7.62 19.05 56.19 17.14 0.83
When the OCS dose is ≤5 mg prednisolone 0.95 15.24 13.33 53.33 17.14 0.70
Definition of abbreviations: ABPA = allergic bronchopulmonary aspergillosis; EGPA, eosinophilic granulomatosis with polyangiitis; OCS = oral 
corticosteroid.
*Note that statements are ordered by mean rank score. 
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Table 3. Consensus Statements Concerning Development of an OCS Tapering Algorithm
Positive consensus Controversial
 The initial tapering of high OCS doses (e.g. >20 mg/day) can proceed at a faster pace
(e.g. –10 mg/week, or 30–50% reductions every 2–4 weeks)
 OCS tapering should be gradual, with 2.5–5 mg steps every 0.5–2 weeks until an agreed-upon 
threshold is achieved (e.g. 5–10 mg/day), and then proceeds at a slower pace (1–2.5 mg every 
1–2 weeks)
 When a reduction in OCS by 5 mg weekly fails, a slower and lower dose reduction of 
1 mg/week should be attempted
 If mild symptoms occur, maintain the current dosage; they are likely to resolve as endogenous 
axis recovery occurs
 If intolerable symptoms occur, return to the previous (efficacious) dose, and then later 
consider re-attempting tapering at a slower pace
 In general, the speed of tapering 
should not exceed a reduction of 
5 mg/week
 OCS tapering should incorporate 
every-other-day OCS reductions 
(especially prior to 
discontinuation) to allow recovery 
of the endogenous axis
 OCS tapering should be gradual by 
reducing the OCS dose by 30–50% 
every 2–4 weeks
Definition of abbreviations: OCS = oral corticosteroid.
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Table 4. Minimal Checklist for Adverse Effect Screening
Positive consensus Controversial




 Cataracts and glaucoma
 Weight change
 Fracture risk score (e.g. FRAX)
 Cardiovascular risk score
 Lipid panel
 Fluid retention
Definition of abbreviations: FRAX = Fracture Risk Assessment Tool.
Adverse effects are not ordered/hierarchized, and should be given equal consideration.  
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1
Online Data Supplement:
Expert Consensus on the Tapering of Oral Corticosteroids for the Treatment of Asthma: A Delphi Study
Carey M. Suehs, Andrew Menzies-Gow, David Price, Eugene R. Bleecker, Giorgio Walter Canonica, Mark Gurnell, Arnaud 
Bourdin on behalf of the Oral Corticosteroids Tapering Delphi Expert Panel*
Results from the three rounds of ranking in the OCS Tapering Delphi project (for items ranked with a five-point Likert scale). For each item, the round 
and sample size are given along with the percentage of experts that chose a given rank. Darker shades of green signify greater percentage consensus. The 


















In general, our goal should be to not use OCS. When nevertheless required, dose and 
duration should be minimized. 1 . 1 . a 1 108 2.78 0.93 0.93 19.44 75.93 1.65 Positive
Short-term (e.g. <15 days) OCS use is appropriate in asthma patients during acute, non-resolutive exacerbation. 1 . 2 . a 1 108 0 0.93 5.56 54.63 38.89 1.31 Positive
Short-term (e.g. <15 days) OCS use is appropriate in asthma patients during acute, life-threatening, exacerbation. 1 . 2 . b 1 108 0 0 0 22.22 77.78 1.78 Positive
Short-term (e.g. <15 days) OCS use is appropriate in asthma patients during eosinophilic
or allergic exacerbation. 1 . 2 . c 1 108 0 3.7 12.04 46.3 37.96 1.19 Positive
Short-term (e.g. <15 days) OCS use is appropriate in asthma patients in the context of an 1 108 4.63 10.19 15.74 45.37 24.07 0.74 Controversial
asthma management plan. 1 . 2 . d 2 113 2.65 7.96 8.85 69.03 11.5 0.79 Positive
Short-term (e.g. <15 days) OCS use is appropriate in asthma patients to avoid hospitalization. 1 . 2 . e 1 108 2.78 11.11 10.19 48.15 27.78 0.87 Positive
1 108 19.44 34.26 24.07 19.44 2.78 -0.48 Controversial
Short-term (e.g. <15 days) OCS use is appropriate in asthma patients to palliate the 2 113 16.81 32.74 18.58 27.43 4.42 -0.3 Controversial
unavailability of hospitalization services. 1 . 2 . f 3 111 14.41 32.43 22.52 22.52 8.11 -0.23 Controversial
Short-term (e.g. <15 days) OCS use is never appropriate in asthma patients. 1 . 2 . g 1 108 71.3 23.15 2.78 2.78 0 -1.63 Negative
As concerns dosages for short courses of OCS for the treatment of asthma exacerbations, 1 108 2.78 37.96 14.81 35.19 9.26 0.1 Controversial
individual tailoring is required to such an extent that the systematic application of "ideal" 2 112 5.36 31.25 19.64 38.39 5.36 0.07 Controversial
doses is unlikely. 1 . 5 . a 3 111 4.5 39.64 12.61 39.64 3.6 -0.02 Controversial
1 108 1.85 21.3 20.37 45.37 11.11 0.43 Controversial
Dosages for short courses of OCS for the treatment of asthma exacerbations should remain stable. 2 112 3.57 19.64 22.32 47.32 7.14 0.35 Controversial
1 . 5 . b 3 111 0.9 16.22 19.82 52.25 10.81 0.56 Controversial
Dosages for short courses of OCS for the treatment of asthma exacerbations should be progressively escalated. 1 . 5 . c 1 108 26.85 53.7 8.33 7.41 3.7 -0.93 Negative
Maintenance OCS therapy is appropriate (and does not require further improvement) in severe 
asthmatics who are well controlled with a low dose of OCS (e.g. 5 mg/day or less of prednisone). 1 . 6 . a 1 108 15.74 54.63 12.96 13.89 2.78 -0.67 Negative
Maintenance OCS therapy is appropriate (and does not require further improvement) in 1 108 5.56 14.81 13.89 59.26 6.48 0.46 Controversial
severe asthmatics with inadequate control despite optimization of alternative (Step 5). 1 . 6 . b 2 111 0.9 17.12 11.71 61.26 9.01 0.6 Positive
Maintenance OCS therapy is appropriate (and does not require further improvement) in
severe asthmatics with poor inhaler compliance/technique. 1 . 6 . c 1 108 56.48 35.19 4.63 3.7 0 -1.44 Negative
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1 108 30.56 38.89 24.07 6.48 0 -0.94 Controversial
Maintenance OCS therapy is appropriate (and does not require further improvement) in 2 111 9.01 45.05 29.73 14.41 1.8 -0.45 Controversial
severe asthmatics with low-T2 phenotypes. 1 . 6 . d 3 111 13.51 52.25 24.32 9.01 0.9 -0.68 Controversial
1 108 18.52 29.63 19.44 31.48 0.93 -0.33 Controversial
Maintenance OCS therapy is appropriate (and does not require further improvement) in 2 111 6.31 36.94 24.32 30.63 1.8 -0.15 Controversial
severe asthmatics with high T2 phenotypes/eosinophils. 1 . 6 . e 3 111 13.51 36.04 24.32 24.32 1.8 -0.35 Controversial
Maintenance OCS therapy is appropriate (and does not require further improvement) in 1 108 3.7 22.22 30.56 36.11 7.41 0.21 Controversial
severe asthmatics when it results in an overall reduction in OCS exposure (i.e. the total 2 111 0.9 14.41 22.52 58.56 3.6 0.5 Controversial
mg of OCS exposure per year; e.g. 5 mg/day is a 33% reduction when compared to 10) 1 . 6 . f 3 111 3.6 15.32 18.02 58.56 4.5 0.45 Controversial
Maintenance OCS therapy is appropriate (and does not require further improvement) in 1 108 1.85 7.41 25 59.26 6.48 0.61 Controversial
severe asthmatics if when trying to taper OCS there is an adverse effect or comorbidity. 1 . 6 . g 2 111 0 8.11 18.02 69.37 4.5 0.7 Positive
1 108 6.48 11.11 12.96 56.48 12.96 0.58 Controversial
Maintenance OCS therapy is appropriate (and does not require further improvement) in 2 111 3.6 12.61 18.02 52.25 13.51 0.59 Controversial
severe asthmatics with primary or secondary adrenal insufficiency. 1 . 6 . h 3 111 6.31 16.22 18.02 48.65 10.81 0.41 Controversial
Maintenance OCS therapy is never appropriate in severe asthmatics. 1 . 6 . i 1 108 27.78 43.52 15.74 10.19 2.78 -0.83 Negative
As concerns maintenance OCS therapy, individual tailoring is required to such an extent
that the systematic application of "ideal" doses is unlikely. 1 . 8 . a 1 108 1.85 16.67 13.89 42.59 25 0.72 Controversial
As concerns maintenance OCS therapy, individual tailoring is required to such an extent
that the systematic application of "ideal" doses is unlikely. 1 . 8 . a 2 111 0.9 17.12 9.91 56.76 15.32 0.68 Positive
1 108 3.7 35.19 19.44 38.89 2.78 0.02 Controversial
An adequate response to long-term OCS in asthmatics can be characterized as: 2 110 5.45 29.09 26.36 37.27 1.82 0.01 Controversial
normalization of lung function. 1 . 9 . a 3 109 1.83 30.28 20.18 47.71 0 0.14 Controversial
1 108 4.63 24.07 19.44 49.07 2.78 0.21 Controversial
An adequate response to long-term OCS in asthmatics can be characterized as: 2 110 0 30 30.91 38.18 0.91 0.1 Controversial
a stable peak flow during the last week of treatment. 1 . 9 . b 3 109 0.92 23.85 25.69 49.54 0 0.24 Controversial
1 108 5.56 20.37 27.78 39.81 6.48 0.21 Controversial
An adequate response to long-term OCS in asthmatics can be characterized as: 2 110 3.64 25.45 25.45 43.64 1.82 0.15 Controversial
suppression of blood eosinophils/other T2 biomarkers. 1 . 9 . c 3 109 1.83 26.61 20.18 50.46 0.92 0.22 Controversial
An adequate response to long-term OCS in asthmatics can be characterized as:
improvement in the Asthma Control Questionnaire score (MCID = 0.5) or the Asthma
Control Test (ACT) (MCID = 5). 1 . 9 . d 1 108 0.93 6.48 7.41 72.22 12.96 0.9 Positive
An adequate response to long-term OCS in asthmatics can be characterized as:
decreasing the exacerbation rate to <2/year. 1 . 9 . e 1 108 0.93 4.63 12.96 63.89 17.59 0.93 Positive
1 108 0.93 24.07 32.41 37.04 5.56 0.22 Controversial
An adequate response to long-term OCS in asthmatics can be characterized as: 2 110 0.91 26.36 16.36 49.09 7.27 0.35 Controversial
decreasing the exacerbation rate by at least 30%. 1 . 9 . f 3 109 0 11.93 19.27 62.39 6.42 0.63 Controversial
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An adequate response to long-term OCS in asthmatics can be characterized as:
decreasing the exacerbation rate by at least 50%. 1 . 9 . g 1 108 0 7.41 14.81 57.41 20.37 0.91 Positive
An adequate response to long-term OCS in asthmatics can be characterized as:
decreasing hospitalizations for asthma to 0 per year. 1 . 9 . h 1 108 0.93 5.56 11.11 56.48 25.93 1.01 Positive
1 108 0.93 12.96 19.44 56.48 10.19 0.62 Controversial
An adequate response to long-term OCS in asthmatics can be characterized as: 2 110 0.91 14.55 16.36 60.91 7.27 0.59 Controversial
a decreased need for rescue treatments. 1 . 9 . i 3 109 0.92 9.17 12.84 72.48 4.59 0.71 Positive
An adequate response to long-term OCS in asthmatics can be characterized as:
when a clinical improvement is obtained that outweighs risks/harms. 1 . 9 . j 1 108 0 3.7 12.96 60.19 23.15 1.03 Positive
An adequate response to long-term OCS in asthmatics can be characterized as:
improvement in asthma-related daily limitations/quality of life. 1 . 9 . k 1 108 1.85 6.48 14.81 70.37 6.48 0.73 Positive
1 108 2.78 19.44 33.33 41.67 2.78 0.22 Controversial
An adequate response to long-term OCS in asthmatics can be characterized as: 2 110 0.91 18.18 33.64 45.45 1.82 0.29 Controversial
improvement in symptoms related to chronic sinusitis/nasal polyps. 1 . 9 . l 3 109 0.92 16.51 29.36 52.29 0.92 0.36 Controversial
An adequate response to long-term OCS in asthmatics can be characterized as:
return to work (which would have been impossible without OCS). 1 . 9 . m 1 108 0.93 2.78 16.67 68.52 11.11 0.86 Positive
OCS may be used as a temporary measure in patients having recurrent eosinophilic
asthma exacerbations whilst completing severe asthma assessments. 1 . 10 . a 1 108 1.85 8.33 13.89 62.96 12.96 0.77 Positive
The yearly cumulative dose of OCS should be monitored as a marker of asthma control. 1 . 10 . b 1 108 0 2.78 6.48 63.89 26.85 1.15 Positive
1 108 0 17.59 25.93 48.15 8.33 0.47 Controversial
2 108 1.85 17.59 22.22 54.63 3.7 0.41 Controversial
OCS therapy can be used to estimate the best obtainable improvement of asthma symptoms. 1 . 10 . c 3 109 0.92 22.02 11.93 59.63 5.5 0.47 Controversial
Short-term, prophylactic OCS use is appropriate in asthma patients when early 1 108 4.63 30.56 20.37 42.59 1.85 0.06 Controversial
signs/symptoms of significant exacerbation appear, if the patient is adherent with proper 2 108 4.63 27.78 22.22 42.59 2.78 0.11 Controversial
use of daily asthma therapy. 1 . 10 . d 3 109 4.59 30.28 15.6 47.71 1.83 0.12 Controversial
1 108 4.63 24.07 35.19 34.26 1.85 0.05 Controversial
OCS can also be considered in patients with fixed airflow obstruction which becomes 2 108 1.85 26.85 29.63 40.74 0.93 0.12 Controversial
reversible on OCS (infrequent). 1 . 10 . e 3 109 2.75 21.1 31.19 44.04 0.92 0.19 Controversial
1 108 2.78 21.3 33.33 39.81 2.78 0.19 Controversial
Asthma patients who have a second exacerbation within 6 weeks of a short "burst" 2 108 2.78 28.7 18.52 46.3 3.7 0.19 Controversial
prednisone-treated exacerbation should have a longer, tapering course of prednisone. 1 . 11 . a 3 109 1.83 18.35 23.85 53.21 2.75 0.37 Controversial
1 108 2.78 20.37 18.52 52.78 5.56 0.38 Controversial
In adults and adolescents receiving maintenance OCS for asthma, the dose should be at 2 108 0.93 19.44 26.85 46.3 6.48 0.38 Controversial
least doubled to define an exacerbation. 1 . 11 . b 3 109 2.75 11.93 16.51 62.39 6.42 0.58 Controversial
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1 108 1.85 14.81 19.44 53.7 10.19 0.56 Controversial
Patients hospitalized for asthma exacerbation and treated with systemic corticosteroids should be 2 108 0.93 22.22 18.52 51.85 6.48 0.41 Controversial
prescribed a short course (for example 5 days) of OCS upon discharge from the hospital. 1 . 11 . c 3 109 0 18.35 20.18 51.38 10.09 0.53 Controversial
1 108 5.56 25 26.85 33.33 9.26 0.16 Controversial
2 108 6.48 34.26 29.63 24.07 5.56 -0.12 Controversial
Prednisolone assays should be used in standard practice to verify OCS adherence. 1 . 12 . a 3 109 5.5 35.78 22.94 29.36 6.42 -0.05 Controversial
1 108 11.11 30.56 42.59 15.74 0 -0.37 Controversial
2 108 13.89 32.41 36.11 16.67 0.93 -0.42 Controversial
A 9AM cortisol test is sufficient for determining if a patient is OCS compliant. 1 . 12 . b 3 109 11.93 37.61 29.36 20.18 0.92 -0.39 Controversial
1 108 0.93 13.89 17.59 36.11 31.48 0.83 Controversial
Long-acting or methylprednisolone injections are not necessary. 1 . 13 . a 2 108 0 13.89 15.74 47.22 23.15 0.8 Positive
Patients receiving frequent methylprednisolone injections for asthma treatment or
exacerbations are at the same or similar risk of suffering side effects from steroids and
developing adrenal insufficiency as those receiving OCS. 1 . 13 . b 1 108 2.78 14.81 7.41 35.19 39.81 0.94 Positive
Long-acting or methylprednisolone injections are not superior to orally administered glucocorticoids. 1 . 13 . c 1 108 0 6.48 13.89 52.78 26.85 1 Positive
Chronic OCS treatment of asthma in the pediatric age should be a rare exception. 1 . 14 . a 1 108 0 0 14.81 29.63 55.56 1.41 Positive
OCS can lead to several systemic side-effects and growth deficits in pediatric patients. 1 . 14 . b 1 108 0 0 11.11 25 63.89 1.53 Positive
1 108 25.93 35.19 29.63 9.26 0 -0.78 Controversial
2 108 14.81 41.67 29.63 12.96 0.93 -0.56 Controversial
Methotrexate is a useful steroid-sparing agent in asthma. 1 . 16 . a 3 109 14.68 48.62 26.61 8.26 1.83 -0.66 Controversial
1 108 25.93 37.04 31.48 5.56 0 -0.83 Controversial
2 108 16.67 50.93 25.93 5.56 0.93 -0.77 Controversial
Azathioprine is a useful steroid-sparing agent in asthma. 1 . 16 . b 3 109 15.6 56.88 21.1 6.42 0 -0.82 Negative
1 108 25 35.19 33.33 6.48 0 -0.79 Controversial
2 108 16.67 39.81 38.89 3.7 0.93 -0.68 Controversial
Mycophenolat mofetil is a useful steroid-sparing agent in asthma. 1 . 16 . c 3 109 14.68 47.71 33.94 3.67 0 -0.73 Controversial
1 108 5.56 25.93 31.48 36.11 0.93 0.01 Controversial
2 108 2.78 27.78 30.56 37.04 1.85 0.07 Controversial
Azithromycin is a useful steroid-sparing agent in asthma. 1 . 16 . d 3 109 2.75 26.61 32.11 35.78 2.75 0.09 Controversial
1 108 1.85 23.15 20.37 42.59 12.04 0.4 Controversial
2 108 3.7 23.15 24.07 39.81 9.26 0.28 Controversial
The most useful OCS-sparing strategy is high-dose inhaled steroid in asthma. 1 . 16 . e 3 109 1.83 13.76 24.77 51.38 8.26 0.5 Controversial
1 108 6.48 24.07 45.37 20.37 3.7 -0.09 Controversial
2 108 3.7 21.3 41.67 31.48 1.85 0.06 Controversial
Bronchial thermoplasty is a useful steroid-sparing strategy in asthma. 1 . 16 . f 3 109 3.67 25.69 43.12 26.61 0.92 -0.05 Controversial
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Biologicals, such as IL5 and IL4Ra targeting drugs, are useful sparing agents in asthma. 1 . 16 . g 1 108 0.93 0 3.7 19.44 75.93 1.69 Positive
There is a need for OCS-sparing agents. 1 . 16 . h 1 108 0 0 1.85 39.81 58.33 1.56 Positive
Patients on maintenance OCS for severe asthma should be systematically assessed for suitability of biologicals. 1 . 17 . a 1 108 0 0 1.85 18.52 79.63 1.78 Positive
OCS may be used as a provisional strategy for difficult to control, eosinophilic/T2 asthma
until an effective biological treatment is available for the patient. 1 . 17 . b 1 108 1.85 2.78 9.26 67.59 18.52 0.98 Positive
The daily dose of OCS treatment may represent a reliable marker for the evaluation of
biological treatment response. 1 . 17 . c 1 108 0.93 7.41 12.04 49.07 30.56 1.01 Positive
1 108 8.33 50 13.89 19.44 8.33 -0.31 Controversial
Patients should not have extra OCS at home because the risk of self treatment becoming 2 107 9.35 50.47 10.28 23.36 6.54 -0.33 Controversial
a habit is too high. 1 . 18 . a 3 109 11.93 44.95 13.76 22.02 7.34 -0.32 Controversial
If OCS is to be used, preparations with lower adrenal suppression should be chosen at the
lowest effective dose administered in the morning. 1 . 18 . b 1 108 0.93 0.93 14.81 58.33 25 1.06 Positive
Establishing equivalence between ICS and OCS in children and in adults (systemic
distribution of ICS) is of major importance. 1 . 18 . c 1 108 0 4.63 23.15 52.78 19.44 0.87 Positive
Tapering (down to a minimal efficacious dose or complete weaning if possible) should be 
attempted in all asthma patients receiving maintenance OCS therapy, regardless of comorbidities. 2 . 1 . a 1 105 0 1.9 1.9 37.14 59.05 1.53 Positive
The rhythm and speed of OCS tapering requires individualization for each patient. 2 . 1 . b 1 105 0 1.9 2.86 54.29 40.95 1.34 Positive
Proceeding towards a tapering attempt is particularly appropriate when: patients on
maintenance OCS have gained control (for a minimum, agreed-upon time). 2 . 2 . a 1 105 0 0 3.81 59.05 37.14 1.33 Positive
Proceeding towards a tapering attempt is particularly appropriate when: biological
treatment has been initiated and results in asthma control. 2 . 2 . b 1 105 0 0.95 0.95 25.71 72.38 1.7 Positive
Proceeding towards a tapering attempt is particularly appropriate when: a patient
exhibits symptoms/comorbidities likely linked to OCS. 2 . 2 . c 1 105 0 1.9 2.86 41.9 53.33 1.47 Positive
Proceeding towards a tapering attempt is particularly appropriate when: there is a
reasonable likelihood of hypothalamic-pituitary-adrenal axis recovery. 2 . 2 . d 1 105 0 1.9 11.43 54.29 32.38 1.17 Positive
Proceeding towards a tapering attempt is particularly appropriate when: the intensity or
duration of OCS treatment gives reason for concern. 2 . 2 . e 1 105 0 0 3.81 59.05 37.14 1.33 Positive
Proceeding towards a tapering attempt is particularly appropriate when: the patient does
not appear to respond to OCS treatment. 2 . 2 . f 1 105 0 0.95 0.95 35.24 62.86 1.6 Positive
Tapering OCS should NOT be attempted in patients who: have demonstrated potentially 1 105 1.9 18.1 18.1 56.19 5.71 0.46 Controversial
harmful outcomes during previous weaning attempts (and all available medications have 2 106 0.94 17.92 22.64 51.89 6.6 0.45 Controversial
been appropriately initiated/tested). 2 . 4 . a 3 109 0.92 22.94 13.76 59.63 2.75 0.4 Controversial
Page 47 of 71
 AJRCCM Articles in Press. Published October 28, 2020 as 10.1164/rccm.202007-2721OC 



















Tapering OCS should NOT be attempted in patients who: have EGPA that relapses during
tapering (and no other changes can be proposed). 2 . 4 . b 1 105 0.95 3.81 12.38 66.67 16.19 0.93 Positive
Tapering OCS should NOT be attempted in patients who: have ABPA that relapses during 0
tapering (and no other changes can be proposed). 2 . 4 . c 1 105 9.52 19.05 61.9 9.52 0.71 Positive
1 105 4.76 11.43 22.86 52.38 8.57 0.49 Controversial
Tapering OCS should NOT be attempted in patients who: have proven primary or 2 106 5.66 21.7 17.92 47.17 7.55 0.29 Controversial
secondary adrenal insufficiency. 2 . 4 . d 3 109 4.59 29.36 18.35 42.2 5.5 0.15 Controversial
1 105 3.81 17.14 20 47.62 11.43 0.46 Controversial
2 106 1.89 20.75 14.15 55.66 7.55 0.46 Controversial
Tapering OCS should NOT be attempted in patients who: have uncontrolled asthma. 2 . 4 . e 3 109 0 21.1 13.76 55.96 9.17 0.53 Controversial
1 105 5.71 24.76 27.62 32.38 9.52 0.15 Controversial
2 106 4.72 27.36 29.25 30.19 8.49 0.1 Controversial
Tapering OCS should NOT be attempted in patients who: have uncontrolled T2 high inflammation. 2 . 4 . f 3 109 1.83 28.44 25.69 40.37 3.67 0.16 Controversial
OCS tapering should be faster in patients who have been on maintenance OCS for shorter
periods (less than 6 months for example). 2 . 5 . a 1 105 0 17.14 12.38 56.19 14.29 0.68 Positive
1 105 0.95 30.48 31.43 34.29 2.86 0.08 Controversial
2 106 2.83 34.91 29.25 31.13 1.89 -0.06 Controversial
OCS tapering should be slower in patients who had a slow response to OCS (and vice-versa). 2 . 5 . b 3 108 0.93 37.96 29.63 31.48 0 -0.08 Controversial
1 105 0 18.1 23.81 44.76 13.33 0.53 Controversial
2 106 0.94 10.38 19.81 61.32 7.55 0.64 Controversial
The speed of OCS tapering depends on the known rapidity of action of the sparing drug introduced. 2 . 5 . c 3 108 0 17.59 20.37 54.63 7.41 0.52 Controversial
The speed of OCS tapering depends on the history of and future risk for adverse events. 2 . 5 . d 1 105 0 5.71 10.48 70.48 13.33 0.91 Positive
The speed of OCS tapering depends on the type of comorbidity present (for EGPA, for
example, tapering plans proposed in RCTs are used). 2 . 5 . e 1 105 0 1.9 13.33 66.67 18.1 1.01 Positive
OCS tapering should be based on patient collaboration and experience with side effects. 2 . 5 . f 1 105 0 1.9 13.33 62.86 21.9 1.05 Positive
1 105 0.95 28.57 36.19 32.38 1.9 0.06 Controversial
2 106 1.89 37.74 30.19 28.3 1.89 -0.09 Controversial
OCS tapering should be guided by biomarkers at each weaning step. 2 . 5 . g 3 108 0.93 50 21.3 25.93 1.85 -0.22 Controversial
1 105 0.95 28.57 29.52 40 0.95 0.11 Controversial
2 106 1.89 27.36 20.75 48.11 1.89 0.21 Controversial
OCS tapering should be gradual, by reducing the OCS dose by 30–50% every 24 weeks. 2 . 6 . a 3 107 0 19.63 12.15 67.29 0.93 0.5 Controversial
OCS tapering should be gradual, with 2.5–5 mg steps every 0.5–2 weeks until an agreed-upon threshold is 
achieved (e.g. 5–10 mg/day), and then proceeds at a slower pace (1–2.5 mg every 1–2 weeks). 2 . 6 . b 1 105 0 3.81 13.33 72.38 10.48 0.9 Positive
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1 105 0 26.67 24.76 39.05 9.52 0.31 Controversial
2 106 1.89 23.58 17.92 50.94 5.66 0.35 Controversial
In general, the speed of tapering should not exceed a reduction of 5 mg per week. 2 . 6 . c 3 107 0 30.84 14.95 48.6 5.61 0.29 Controversial
1 105 0.95 16.19 19.05 55.24 8.57 0.54 Controversial
The initial tapering of high OCS doses (e.g. >20 mg per day) can proceed at a faster pace 2 106 0 13.21 16.98 66.98 2.83 0.59 Controversial
(e.g. -10 mg per week, or 30–50% reductions every 2–4 weeks). 2 . 6 . d 3 107 1.87 8.41 14.95 70.09 4.67 0.67 Positive
When a reduction in OCS by 5 mg weekly fails, a slower and lower dose reduction of 1 mg
per week should be attempted. 2 . 6 . e 1 105 0 5.71 12.38 72.38 9.52 0.86 Positive
1 105 1.9 16.19 27.62 44.76 9.52 0.44 Controversial
OCS tapering should incorporate every-other-day OCS reductions (especially prior to 2 106 2.83 19.81 28.3 46.23 2.83 0.26 Controversial
discontinuation) to allow recovery of the endogenous axis. 2 . 6 . f 3 107 2.8 15.89 26.17 50.47 4.67 0.38 Controversial
If intolerable symptoms occur, return to the previous (efficacious) dose, and then later
consider re-attempting tapering at a slower pace. 2 . 6 . g 1 105 0 0 3.81 75.24 20.95 1.17 Positive
1 105 0 6.67 23.81 65.71 3.81 0.67 Controversial
If mild symptoms occur, maintain the current dosage; they are likely to resolve as 2 106 0.94 7.55 23.58 66.04 1.89 0.6 Controversial
endogenous axis recovery occurs. 2 . 6 . h 3 107 0 7.48 19.63 69.16 3.74 0.69 Positive
1 105 2.86 28.57 43.81 24.76 0 -0.1 Controversial
2 106 1.89 44.34 28.3 23.58 1.89 -0.21 Controversial
A tapering trial should end when: biomarkers trend toward abnormal. 2 . 7 . a 3 107 1.87 44.86 23.36 28.97 0.93 -0.18 Controversial
A tapering trial should end when: symptoms trend toward loss of control (retain lowest
dose that maintains clinical benefit). 2 . 7 . b 1 105 0 5.71 2.86 81.9 9.52 0.95 Positive
1 105 4.76 40.95 25.71 24.76 3.81 -0.18 Controversial
2 106 5.66 43.4 29.25 18.87 2.83 -0.3 Controversial
A tapering trial should end when: the patient is not motivated to continue. 2 . 7 . c 3 107 1.87 43.93 24.3 28.04 1.87 -0.16 Controversial
1 105 3.81 30.48 35.24 25.71 4.76 -0.03 Controversial
2 106 2.83 32.08 23.58 39.62 1.89 0.06 Controversial
Peak expiratory flow is a useful biomarker during OCS tapering. 2 . 8 . a 3 106 0.94 33.02 16.04 49.06 0.94 0.16 Controversial
1 105 1.9 23.81 22.86 44.76 6.67 0.3 Controversial
2 106 0 26.42 22.64 46.23 4.72 0.29 Controversial
Forced expiratory volume in 1 second (spirometry) is a useful biomarker during OCS tapering. 2 . 8 . b 3 106 0.94 26.42 16.98 50.94 4.72 0.32 Controversial
1 105 0 11.43 29.52 53.33 5.71 0.53 Controversial
2 106 0 15.09 20.75 55.66 8.49 0.58 Controversial
Fraction exhaled nitric oxide is a useful biomarker during OCS tapering. 2 . 8 . c 3 106 0.94 14.15 24.53 54.72 5.66 0.5 Controversial
1 105 0 13.33 27.62 50.48 8.57 0.54 Controversial
2 106 1.89 18.87 24.53 48.11 6.6 0.39 Controversial
Peripheral eosinophils are a useful biomarker during OCS tapering. 2 . 8 . d 3 106 0 15.09 23.58 55.66 5.66 0.52 Controversial
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1 105 2.86 20 32.38 35.24 9.52 0.29 Controversial
2 106 6.6 21.7 23.58 42.45 5.66 0.19 Controversial
Sputum eosinophils are a useful biomarker during OCS tapering. 2 . 8 . e 3 106 5.66 19.81 32.08 38.68 3.77 0.15 Controversial
1 105 15.24 34.29 37.14 11.43 1.9 -0.5 Controversial
Bronchoalveolar lavage fluid (BAL) eosinophils are a useful biomarker during OCS 2 106 14.15 44.34 28.3 12.26 0.94 -0.58 Controversial
tapering. 2 . 8 . f 3 106 16.98 43.4 27.36 10.38 1.89 -0.63 Controversial
Asthma control questionnaires (ACT, ACQ) are a useful biomarker during OCS tapering. 2 . 8 . g 1 105 0.95 4.76 12.38 61.9 20 0.95 Positive
1 105 2.86 12.38 20.95 54.29 9.52 0.55 Controversial
2 106 4.72 19.81 25.47 44.34 5.66 0.26 Controversial
Adrenal insufficiency assessments are a useful biomarker during OCS tapering. 2 . 8 . h 3 106 4.72 22.64 22.64 45.28 4.72 0.23 Controversial
1 105 24.76 31.43 24.76 15.24 3.81 -0.58 Controversial
2 106 21.7 36.79 22.64 16.04 2.83 -0.58 Controversial
Biomarker guidance is useless or too troublesome during OCS tapering. 2 . 8 . i 3 106 11.32 51.89 21.7 13.21 1.89 -0.58 Controversial
Cautious, slow tapering is particularly appropriate for patients who: have comorbidities that respond to OCS. 2 . 9 . a 1 105 0 3.81 9.52 70.48 16.19 0.99 Positive
Cautious, slow tapering is particularly appropriate for patients who: have had life-threatening attacks. 2 . 9 . b 1 105 0.95 3.81 3.81 60 31.43 1.17 Positive
Cautious, slow tapering is particularly appropriate for patients who: have been
dependent on systemic steroids for an extended period of time (e.g. 6 months or more). 2 . 9 . c 1 105 0 2.86 6.67 63.81 26.67 1.14 Positive
Complete OCS cessation (weaning) can be implemented: when the OCS dose is less than
or equal to 5 mg prednisolone. 2 . 10 . a 1 105 0.95 15.24 13.33 53.33 17.14 0.7 Positive
Complete OCS cessation (weaning) can be implemented: following a short course of OCS
treatment that lasted for 5–7 days. 2 . 10 . b 1 105 0.95 1.9 1.9 44.76 50.48 1.42 Positive
Complete OCS cessation (weaning) can be implemented: following a short course of OCS
treatment if patients are on inhaled anti inflammatory therapy. 2 . 10 . c 1 105 1.9 1.9 2.86 48.57 44.76 1.32 Positive
1 105 0 18.1 27.62 41.9 12.38 0.49 Controversial
Complete OCS cessation (weaning) can be implemented: when no severe exacerbations 2 106 1.89 22.64 16.98 51.89 6.6 0.39 Controversial
have occurred during the last 4 weeks. 2 . 10 . d 3 106 0.94 22.64 15.09 58.49 2.83 0.4 Controversial
Complete OCS cessation (weaning) can be implemented: when there is no evidence of adrenal insufficiency. 2 . 10 . e 1 105 0.95 6.67 13.33 59.05 20 0.9 Positive
Complete OCS cessation (weaning) can be implemented: when there is no evidence of EGPA or ABPA. 2 . 10 . f 1 105 0 7.62 19.05 56.19 17.14 0.83 Positive
Complete OCS cessation (weaning) can be implemented: when a sparing strategy has been initiated. 2 . 10 . g 1 105 0.95 2.86 14.29 54.29 27.62 1.05 Positive
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Complete OCS cessation (weaning) can be implemented: when the patient has agreed to cessation. 2 . 10 . h 1 105 1.9 4.76 20 50.48 22.86 0.88 Positive
1 105 0 14.29 34.29 44.76 6.67 0.44 Controversial
Pulmonary rehabilitation can be helpful before OCS tapering to improve physical activity 2 106 0 16.98 19.81 50.94 12.26 0.58 Controversial
and decrease dyspnea. It can facilitate OCS tapering. 2 . 11 . a 3 106 1.89 11.32 20.75 53.77 12.26 0.63 Controversial
OCS tapering should be re-attempted every time a new biological treatment for
eosinophilic asthma patients becomes available. 2 . 11 . b 1 105 0 2.86 7.62 57.14 32.38 1.19 Positive
Biological therapies have become an essential support for OCS tapering. 2 . 11 . c 1 105 0.95 0.95 4.76 29.52 63.81 1.54 Positive
Following the initiation of a biological therapy, if weaning is not achieved within 
12 months, consider switching to a different biological. 2 . 11 . d 1 105 0 5.71 10.48 57.14 26.67 1.05 Positive
Not achieving a >50% reduction in OCS dose (or a tolerable daily dose) is a failure for a
given biological therapy that may mandate switching strategies. 2 . 11 . e 1 105 0 5.71 20 59.05 15.24 0.84 Positive
1 105 1.9 15.24 39.05 38.1 5.71 0.3 Controversial
Thermoplasty needs to be considered when OCS tapering fails and no other alternative is 2 106 0 13.21 29.25 50.94 6.6 0.51 Controversial
indicated (biologicals etc). 2 . 11 . f 3 106 0.94 10.38 34.91 44.34 9.43 0.51 Controversial
Poor adherence and inhaler technique should be actively sought and managed to facilitate OCS tapering. 2 . 12 . a 1 105 0 0.95 0.95 32.38 65.71 1.63 Positive
1 105 0.95 23.81 16.19 44.76 14.29 0.48 Controversial
2 106 4.72 27.36 7.55 51.89 8.49 0.32 Controversial
Monitoring during OCS tapering can be based on symptoms in almost all patients. 2 . 12 . b 3 106 0.94 23.58 14.15 55.66 5.66 0.42 Controversial
OCS should be used at a minimum dose, so whenever writing a prescription for OCS, the
option of reducing the dose should always be considered. 2 . 12 . c 1 105 0 2.86 7.62 58.1 31.43 1.18 Positive
Comorbidities should be addressed at all times (not just during tapering). 3 . 1 . a 1 103 0 0 1.94 42.72 55.34 1.53 Positive
Asthma patients receiving OCS therapy are at a higher risk of complications compared to
those without OCS exposure. 3 . 1 . b 1 103 0 0 2.91 29.13 67.96 1.65 Positive
OCS tapering becomes a primary outcome/goal of asthma management when a patient is
affected by OCS-related comorbidities. 3 . 1 . c 1 103 0 2.91 4.85 28.16 64.08 1.53 Positive
The evaluation of comorbidities is mandatory prior to tapering OCS. 3 . 1 . d 1 103 0 3.88 7.77 53.4 34.95 1.19 Positive
In general, the presence of comorbidities should not preclude attempting to taper down
to the lowest efficacious dose or complete withdrawal (if possible). 3 . 1 . e 1 103 0.97 1.94 0.97 60.19 35.92 1.28 Positive
Comorbidities to address prior to or when initiating tapering: those that require or
respond well to OCS treatment (immune diseases, vasculitis, adrenal suppression, etc) 3 . 2 . a 1 103 0 0.97 2.91 55.34 40.78 1.36 Positive
Page 51 of 71
 AJRCCM Articles in Press. Published October 28, 2020 as 10.1164/rccm.202007-2721OC 



















Comorbidities to address prior to or when initiating tapering: respiratory comorbidities 
or those that may cause (or mimic) asthma (rhinosinusitis, nasal polyposis, GERD, bronchiectasis, 
vocal cord dysfunction, inducible laryngeal obstruction, dysfunctional breathing, etc). 3 . 2 . b 1 103 0 3.88 4.85 60.19 31.07 1.18 Positive
Comorbidities to address prior to or when initiating tapering: chronic non-communicable 
diseases often exacerbated by (or even caused by) OCS use (hyperglycemia/diabetes, metabolic 
disease, cardiovascular diseases, high blood pressure, glaucoma, cataract, osteoporosis, etc). 3 . 2 . c 1 103 0 1.94 6.8 54.37 36.89 1.26 Positive
The minimum checklist for comorbidity screening in the OCS-treated population should
include: glycemic control/HbA1c. 3 . 3 . a 1 103 0 0.97 0.97 54.37 43.69 1.41 Positive
The minimum checklist for comorbidity screening in the OCS-treated population should include: blood pressure. 3 . 3 . b 1 103 0 0.97 6.8 58.25 33.98 1.25 Positive
1 103 0 7.77 27.18 54.37 10.68 0.68 Controversial
The minimum checklist for comorbidity screening in the OCS-treated population should 2 106 1.89 24.53 21.7 51.89 0 0.24 Controversial
include: fluid retention. 3 . 3 . c 3 106 1.89 18.87 26.42 50.94 1.89 0.32 Controversial
1 103 0 6.8 25.24 47.57 20.39 0.82 Controversial
The minimum checklist for comorbidity screening in the OCS-treated population should 2 106 1.89 24.53 27.36 44.34 1.89 0.2 Controversial
include: cardiovascular risk score (e.g. CHADS2). 3 . 3 . d 3 106 2.83 21.7 25.47 45.28 4.72 0.27 Controversial
1 103 0 7.77 29.13 48.54 14.56 0.7 Controversial
The minimum checklist for comorbidity screening in the OCS-treated population should 2 106 0.94 23.58 24.53 50 0.94 0.26 Controversial
include: lipid panel. 3 . 3 . e 3 106 2.83 25.47 22.64 47.17 1.89 0.2 Controversial
The minimum checklist for comorbidity screening in the OCS-treated population should
include: fracture risk score (e.g. FRAX). 3 . 3 . f 1 103 0 0 17.48 50.49 32.04 1.15 Positive
The minimum checklist for comorbidity screening in the OCS-treated population should
include: bone density. 3 . 3 . g 1 103 0 0 4.85 49.51 45.63 1.41 Positive
The minimum checklist for comorbidity screening in the OCS-treated population should
include: cataracts and glaucoma. 3 . 3 . h 1 103 0 2.91 10.68 50.49 35.92 1.19 Positive
The minimum checklist for comorbidity screening in the OCS-treated population should
include: growth (pediatric population). 3 . 3 . i 1 103 0 0 3.88 42.72 53.4 1.5 Positive
The minimum checklist for comorbidity screening in the OCS-treated population should
include: weight change. 3 . 3 . j 1 103 0 0.97 6.8 65.05 27.18 1.18 Positive
Comorbidity subsets for whom OCS tapering is a priority: those with evidence of a
clinically significant OCS adverse effect. 3 . 4 . a 1 103 0 0 0.97 38.83 60.19 1.59 Positive
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Comorbidity subsets for whom OCS tapering is a priority: those with chronic non-communicable 
diseases often exacerbated by (or even caused by) OCS use (glucose metabolism, metabolic 
disease, cardiovascular diseases, high blood pressure, glaucoma, cataract, osteoporosis, etc). 3 . 4 . b 1 103 0 0 0.97 45.63 53.4 1.52 Positive
1 103 0 5.83 25.24 48.54 20.39 0.83 Controversial
2 106 0.94 17.92 26.42 48.11 6.6 0.42 Controversial
Comorbidity subsets for whom OCS tapering is a priority: those with a non-T2 phenotype. 3 . 4 . c 3 105 0.95 15.24 21.9 54.29 7.62 0.52 Controversial
Comorbidity subsets for whom OCS tapering is a priority: those with important risk
factors associated with increased OCS-susceptibility... 3 . 4 . d 1 103 0 0 10.68 63.11 26.21 1.16 Positive
Comorbidity subsets for whom OCS tapering is a priority: those with important risk
factors associated with increased OCS-susceptibility... such as age (youth). 3 . 4 . e 1 103 0 0 10.68 50.49 38.83 1.28 Positive
Comorbidity subsets for whom OCS tapering is a priority: those with important risk
factors associated with increased OCS-susceptibility... such as age (elderly). 3 . 4 . f 1 103 0 3.88 16.5 54.37 25.24 1.01 Positive
Comorbidity subsets for whom OCS tapering is a priority: those with important risk
factors associated with increased OCS-susceptibility... such as post-menopausal women. 3 . 4 . g 1 103 0 8.74 19.42 51.46 20.39 0.83 Positive
1 103 0 8.74 32.04 45.63 13.59 0.64 Controversial
Comorbidity subsets for whom OCS tapering is a priority: those with important risk 2 106 0.94 14.15 16.98 61.32 6.6 0.58 Controversial
factors associated with increased OCS-susceptibility... such as gender (female). 3 . 4 . h 3 105 0 8.57 25.71 60 5.71 0.63 Controversial
1 103 0 11.65 30.1 47.57 10.68 0.57 Controversial
Comorbidity subsets for whom OCS tapering is a priority: those with important risk 2 106 0.94 15.09 27.36 52.83 3.77 0.43 Controversial
factors associated with increased OCS-susceptibility... such as vitamin D deficiency. 3 . 4 . i 3 105 0.95 8.57 34.29 53.33 2.86 0.49 Controversial
Comorbidity subsets for whom OCS tapering is a priority: those with important risk 1 103 0 7.77 61.17 23.3 7.77 0.31 Controversial
factors associated with increased OCS-susceptibility... such as known PDGF-D gene 2 106 1.89 13.21 54.72 27.36 2.83 0.16 Controversial
polymorphism. 3 . 4 . j 3 105 0.95 8.57 62.86 23.81 3.81 0.21 Controversial
1 103 0.97 35.92 32.04 25.24 5.83 -0.01 Controversial
2 106 7.55 51.89 15.09 18.87 6.6 -0.35 Controversial
Obese patients should have a polysomnography test prior to tapering. 3 . 6 . a 3 105 1.9 60 22.86 11.43 3.81 -0.45 Controversial
Obesity should be aggressively managed with dietary advice and, where suitable and safe,
consideration of bariatric surgery. 3 . 6 . b 1 103 0 0.97 6.8 63.11 29.13 1.2 Positive
1 103 0 15.53 29.13 50.49 4.85 0.45 Controversial
The risk of triggering a bipolar disorder in predisposed patients on continuous OCS 2 106 2.83 25.47 24.53 42.45 4.72 0.21 Controversial
treatment should be discussed with a psychiatrist. 3 . 7 . a 3 105 1.9 24.76 23.81 45.71 3.81 0.25 Controversial
OCS addiction requires assessment of patient psychological profiles. 3 . 7 . b 1 103 0 7.77 21.36 63.11 7.77 0.71 Positive
1 103 5.83 36.89 31.07 25.24 0.97 -0.21 Controversial
All patients over 65 years with severe asthma Step 5 and cardiac failure, should begin 2 106 4.72 45.28 16.98 31.13 1.89 -0.2 Controversial
tapering only in case of stable cardiac disease.    3 . 8 . a 3 105 4.76 38.1 20.95 33.33 2.86 -0.09 Controversial
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In OCS patients with cardiovascular diseases, a coronarography should be performed
even if the patient has no symptoms. 3 . 8 . b 1 103 11.65 49.51 28.16 9.71 0.97 -0.61 Controversial
In OCS patients with cardiovascular diseases, a coronarography should be performed
even if the patient has no symptoms. 3 . 8 . b 2 106 17.92 56.6 16.98 8.49 0 -0.84 Negative
1 103 4.85 38.83 26.21 26.21 3.88 -0.15 Controversial
Patients >75 years of age with uncontrolled, Step 4–5 asthma and cardiac disease should 2 106 4.72 33.02 23.58 34.91 3.77 0 Controversial
have a cardiology evaluation prior to tapering. 3 . 8 . c 3 105 5.71 45.71 17.14 27.62 3.81 -0.22 Controversial
1 103 0 17.48 33.01 45.63 3.88 0.36 Controversial
2 106 0 23.58 25.47 41.51 9.43 0.37 Controversial
For GINA Step 5 patients, fungal disease must be ruled out in the first weeks of OCS treatment. 3 . 9 . a 3 105 0.95 20 21.9 51.43 5.71 0.41 Controversial
1 103 0.97 25.24 29.13 42.72 1.94 0.19 Controversial
2 106 0.94 26.42 36.79 33.02 2.83 0.1 Controversial
OCS tapering should occur prior to cataract surgery. 3 . 9 . b 3 105 0 20 41.9 34.29 3.81 0.22 Controversial
1 103 3.88 21.36 21.36 48.54 4.85 0.29 Controversial
2 106 4.72 22.64 23.58 41.51 7.55 0.25 Controversial
In patients with EGPA, tapering must be performed in collaboration with a rheumatologist. 3 . 9 . c 3 105 2.86 25.71 20.95 44.76 5.71 0.25 Controversial
1 103 0 2.91 46.6 44.66 5.83 0.53 Controversial
For patients treated with DDAVP (desmopressin), sodium levels should be monitored 2 106 0 4.72 46.23 43.4 5.66 0.5 Controversial
during tapering to avoid significant hyponatremia. 3 . 9 . d 3 105 0 4.76 50.48 41.9 2.86 0.43 Controversial
1 103 0.97 15.53 20.39 57.28 5.83 0.51 Controversial
2 106 3.77 19.81 19.81 51.89 4.72 0.34 Controversial
ACOS/COPD rule-out should be performed for patients with a history of tobacco use or biomass exposure. 3 . 9 . e 3 105 1.9 21.9 8.57 60 7.62 0.5 Controversial
The cost of OCS side effects should be more properly invested in more effective
treatments such as biologicals. 3 . 9 . f 1 103 0 0.97 10.68 50.49 37.86 1.25 Positive
OCS tapering may be necessary for assessing the possibility of EGPA or other systemic vasculitis. 3 . 9 . g 1 103 1.94 3.88 22.33 65.05 6.8 0.71 Positive
Adrenal insufficiency among OCS-treated asthma patients should be regularly assessed. 4 . 1 . a 1 101 1.98 11.88 12.87 57.43 15.84 0.73 Positive
In as much as possible during the tapering process, troublesome signs (such as aches and
pains) of adrenal insufficiency should be symptomatically treated and not viewed as a
reason to give up on tapering altogether. 4 . 1 . b 1 101 0.99 8.91 14.85 62.38 12.87 0.77 Positive
1 101 1.98 3.96 28.71 46.53 18.81 0.76 Controversial
In case of adrenal insufficiency during tapering, hydrocortisone replacement is preferred 2 106 1.89 7.55 27.36 50 13.21 0.65 Controversial
to continued prednisolone, and may ease the tapering process. 4 . 1 . c 3 105 1.9 5.71 27.62 55.24 9.52 0.65 Controversial
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Adrenal insufficiency should be assessed: systematically when the daily dose of OCS is
tapered down to an agreed-upon threshold... 4 . 2 . a 1 101 1.98 9.9 12.87 55.45 19.8 0.81 Positive
1 101 4.95 31.68 35.64 18.81 8.91 -0.05 Controversial
Adrenal insufficiency should be assessed: systematically when the daily dose of OCS is 2 105 2.86 34.29 27.62 28.57 6.67 0.02 Controversial
tapered down to an agreed-upon threshold... such as 3 mg/day. 4 . 2 . b 3 105 4.76 33.33 24.76 33.33 3.81 -0.02 Controversial
1 101 3.96 12.87 24.75 46.53 11.88 0.5 Controversial
Adrenal insufficiency should be assessed: systematically when the daily dose of OCS is 2 105 1.9 18.1 15.24 52.38 12.38 0.55 Controversial
tapered down to an agreed-upon threshold... such as 5 mg/day. 4 . 2 . c 3 105 3.81 13.33 19.05 54.29 9.52 0.52 Controversial
1 101 3.96 31.68 33.66 22.77 7.92 -0.01 Controversial
Adrenal insufficiency should be assessed: systematically when the daily dose of OCS is 2 105 4.76 34.29 36.19 18.1 6.67 -0.12 Controversial
tapered down to an agreed-upon threshold... such as 7.5 mg/day. 4 . 2 . d 3 105 5.71 36.19 24.76 27.62 5.71 -0.09 Controversial
1 101 3.96 17.82 19.8 55.45 2.97 0.36 Controversial
2 105 3.81 22.86 11.43 51.43 10.48 0.42 Controversial
Adrenal insufficiency should be assessed only in selected sub-populations... 4 . 3 . a 3 105 3.81 21.9 10.48 58.1 5.71 0.4 Controversial
Adrenal insufficiency should be assessed only in selected sub-populations... such as those
on regular, long-term OCS therapy. 4 . 3 . b 1 101 0.99 4.95 9.9 62.38 21.78 0.99 Positive
1 101 1.98 23.76 37.62 32.67 3.96 0.13 Controversial
Adrenal insufficiency should be assessed only in selected sub-populations... such as those 2 105 2.86 36.19 25.71 30.48 4.76 -0.02 Controversial
exceeding a cumulative yearly dose of 500 mg OCS. 4 . 3 . c 3 105 0 39.05 32.38 26.67 1.9 -0.09 Controversial
1 101 1.98 19.8 26.73 38.61 12.87 0.41 Controversial
Adrenal insufficiency should be assessed only in selected sub-populations... such as those 2 105 1.9 25.71 24.76 39.05 8.57 0.27 Controversial
exceeding a cumulative yearly dose of 1 g OCS. 4 . 3 . d 3 105 0 20 30.48 43.81 5.71 0.35 Controversial
1 101 1.98 13.86 20.79 41.58 21.78 0.67 Controversial
Adrenal insufficiency should be assessed only in selected sub-populations... such as those 2 105 0.95 17.14 19.05 44.76 18.1 0.62 Controversial
exceeding a cumulative yearly dose of 2 g OCS. 4 . 3 . e 3 105 0 16.19 19.05 48.57 16.19 0.65 Controversial
1 101 1.98 8.91 21.78 39.6 27.72 0.82 Controversial
Adrenal insufficiency should be assessed only in selected sub-populations... such as those 2 105 0.95 13.33 17.14 45.71 22.86 0.76 Controversial
exceeding a cumulative yearly dose of >2 g OCS. 4 . 3 . f 3 105 0.95 14.29 16.19 47.62 20.95 0.73 Controversial
1 101 8.91 53.47 28.71 8.91 0 -0.62 Controversial
Adrenal insufficiency should be assessed only in selected sub-populations... such as those 2 105 11.43 55.24 26.67 5.71 0.95 -0.7 Controversial
who have had two repeated short courses of OCS in a given year. 4 . 4 . a 3 105 7.62 60.95 19.05 12.38 0 -0.64 Controversial
1 101 6.93 46.53 28.71 16.83 0.99 -0.42 Controversial
Adrenal insufficiency should be assessed only in selected sub-populations... such as those 2 105 10.48 40 28.57 18.1 2.86 -0.37 Controversial
who have had three repeated short courses of OCS in a given year. 4 . 4 . b 3 105 5.71 48.57 21.9 22.86 0.95 -0.35 Controversial
1 101 5.94 28.71 26.73 29.7 8.91 0.07 Controversial
Adrenal insufficiency should be assessed only in selected sub-populations... such as those 2 105 3.81 28.57 18.1 41.9 7.62 0.21 Controversial
who have had four repeated short courses of OCS in a given year.    4 . 4 . c 3 105 3.81 28.57 20.95 40.95 5.71 0.16 Controversial
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1 101 2.97 12.87 20.79 43.56 19.8 0.64 Controversial
Adrenal insufficiency should be assessed only in selected sub-populations... such as those 2 105 1.9 12.38 16.19 48.57 20.95 0.74 Controversial
who have had >4 repeated short courses of OCS in a given year. 4 . 4 . d 3 105 1.9 13.33 15.24 54.29 15.24 0.68 Controversial
Adrenal insufficiency should be assessed when signs/symptoms of adrenal insufficiency appear. 4 . 5 . a 1 101 0.99 6.93 5.94 43.56 42.57 1.2 Positive
Adrenal insufficiency should be assessed when OCS tapering trials are unsuccessful. 4 . 5 . b 1 101 0 14.85 10.89 52.48 21.78 0.81 Positive
1 101 1.98 21.78 55.45 18.81 1.98 -0.03 Controversial
In case of adrenal insufficiency during tapering, OCS should be switched to physiological 2 105 0.95 28.57 50.48 16.19 3.81 -0.07 Controversial
doses of hydrocortisone with the following characteristics: 0.25 mg/kg/d. 4 . 6 . a 3 105 1.9 32.38 42.86 20.95 1.9 -0.11 Controversial
1 101 3.96 21.78 43.56 29.7 0.99 0.02 Controversial
In case of adrenal insufficiency during tapering, OCS should be switched to physiological 2 105 3.81 29.52 48.57 16.19 1.9 -0.17 Controversial
doses of hydrocortisone with the following characteristics: 0.50 mg/kg/d. 4 . 6 . b 3 105 1.9 26.67 43.81 26.67 0.95 -0.02 Controversial
1 101 0.99 21.78 32.67 38.61 5.94 0.27 Controversial
In case of adrenal insufficiency during tapering, OCS should be switched to physiological 2 105 2.86 16.19 41.9 31.43 7.62 0.25 Controversial
doses of hydrocortisone with the following characteristics: 15–20 mg/day 4 . 6 . c 3 105 1.9 17.14 43.81 31.43 5.71 0.22 Controversial
In case of adrenal insufficiency during tapering, OCS should be switched to physiological 1 101 4.95 18.81 46.53 28.71 0.99 0.02 Controversial
doses of hydrocortisone with the following characteristics: 30 mg/day in men and 20 mg/day 2 105 4.76 24.76 44.76 23.81 1.9 -0.07 Controversial
in women. 4 . 6 . d 3 105 2.86 25.71 41.9 26.67 2.86 0.01 Controversial
In case of adrenal insufficiency during tapering, OCS should be switched to physiological 
doses of hydrocortisone with the following characteristics: doubling in cases of stress/sick days. 4 . 6 . e 1 101 0.99 5.94 16.83 56.44 19.8 0.88 Positive
1 101 4.95 32.67 33.66 24.75 3.96 -0.1 Controversial
In case of adrenal insufficiency during tapering, OCS should be switched to physiological 2 105 6.67 36.19 27.62 23.81 5.71 -0.14 Controversial
doses of hydrocortisone with the following characteristics: one intake per day. 4 . 6 . f 3 105 9.52 39.05 26.67 21.9 2.86 -0.3 Controversial
1 101 2.97 23.76 31.68 36.63 4.95 0.17 Controversial
In case of adrenal insufficiency during tapering, OCS should be switched to physiological 2 105 1.9 23.81 36.19 31.43 6.67 0.17 Controversial
doses of hydrocortisone with the following characteristics: two intakes per day. 4 . 6 . g 3 105 2.86 14.29 32.38 45.71 4.76 0.35 Controversial
1 101 4.95 40.59 31.68 17.82 4.95 -0.23 Controversial
In case of adrenal insufficiency during tapering, OCS should be switched to physiological 2 105 2.86 41.9 32.38 19.05 3.81 -0.21 Controversial
doses of hydrocortisone with the following characteristics: three intakes per day. 4 . 6 . h 3 105 6.67 34.29 33.33 22.86 2.86 -0.19 Controversial
1 101 5.94 19.8 29.7 41.58 2.97 0.16 Controversial
2 105 6.67 21.9 25.71 41.9 3.81 0.14 Controversial
Hydrocortisone is not obligatory; OCS can be maintained at 2–4 mg once daily (starting at 4 mg) 4 . 7 . a 3 105 3.81 22.86 29.52 40 3.81 0.17 Controversial
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1 101 7.92 19.8 21.78 48.51 1.98 0.17 Controversial
2 105 7.62 18.1 23.81 46.67 3.81 0.21 Controversial
Hydrocortisone is not obligatory; OCS can be maintained at 5 mg once daily. 4 . 7 . b 3 105 4.76 17.14 25.71 49.52 2.86 0.29 Controversial
1 101 13.86 29.7 29.7 25.74 0.99 -0.3 Controversial
2 105 11.43 42.86 26.67 17.14 1.9 -0.45 Controversial
Hydrocortisone is not obligatory; OCS can be maintained at 7.5 mg once daily. 4 . 7 . c 3 105 10.48 37.14 26.67 23.81 1.9 -0.3 Controversial
1 101 2.97 12.87 38.61 37.62 7.92 0.35 Controversial
2 105 1.9 28.57 30.48 34.29 4.76 0.11 Controversial
Switching to hydrocortisone should be performed: as soon as adrenal insufficiency is diagnosed. 4 . 8 . a 3 105 3.81 23.81 25.71 42.86 3.81 0.19 Controversial
1 101 3.96 7.92 26.73 55.45 5.94 0.51 Controversial
Switching to hydrocortisone should be performed: when the patient has been weaned 2 105 2.86 10.48 29.52 53.33 3.81 0.45 Controversial
down to 5 mg OCS (and signs of adrenal insufficiency are present). 4 . 8 . b 3 105 2.86 10.48 23.81 61.9 0.95 0.48 Controversial
1 101 5.94 50.5 32.67 10.89 0 -0.51 Controversial
Switching to hydrocortisone should be performed: when the patient has been weaned 2 105 5.71 47.62 33.33 8.57 4.76 -0.41 Controversial
down to 5 mg OCS (regardless of adrenal insufficiency assessments). 4 . 8 . c 3 105 7.62 46.67 24.76 20 0.95 -0.4 Controversial
1 101 3.96 24.75 35.64 27.72 7.92 0.11 Controversial
Switching to hydrocortisone should be performed: when the patient has been weaned 2 105 3.81 35.24 32.38 23.81 4.76 -0.1 Controversial
down to 7 mg OCS (and signs of adrenal insufficiency are present). 4 . 8 . d 3 105 5.71 35.24 23.81 33.33 1.9 -0.1 Controversial
1 101 6.93 55.45 31.68 2.97 2.97 -0.6 Controversial
Switching to hydrocortisone should be performed: when the patient has been weaned 2 105 6.67 50.48 34.29 4.76 3.81 -0.51 Controversial
down to 7 mg OCS (regardless of adrenal insufficiency assessments). 4 . 8 . e 3 105 9.52 54.29 24.76 9.52 1.9 -0.6 Controversial
1 101 8.91 36.63 31.68 18.81 3.96 -0.28 Controversial
2 105 10.48 29.52 31.43 20.95 7.62 -0.14 Controversial
Switching to hydrocortisone is not obligatory/important when managing adrenal insufficiency. 4 . 8 . f 3 105 15.24 30.48 33.33 16.19 4.76 -0.35 Controversial
1 101 3.96 44.55 27.72 21.78 1.98 -0.27 Controversial
2 105 7.62 42.86 22.86 23.81 2.86 -0.29 Controversial
Adrenal insufficiency should be assessed: using only a fasting morning cortisol. 4 . 9 . a 3 105 4.76 46.67 21.9 23.81 2.86 -0.27 Controversial
1 101 0.99 32.67 35.64 24.75 5.94 0.02 Controversial
2 105 4.76 34.29 28.57 25.71 6.67 -0.05 Controversial
Adrenal insufficiency should be assessed: using only a (short) Synacthen test. 4 . 9 . b 3 105 1.9 40.95 24.76 29.52 2.86 -0.1 Controversial
Adrenal insufficiency should be assessed: using fasting morning cortisol, and in case of
intermediate results, follow up with a (short) Synacthen test. 4 . 9 . c 1 101 0.99 6.93 19.8 55.45 16.83 0.8 Positive
1 101 0 6.93 31.68 54.46 6.93 0.61 Controversial
Adrenal insufficiency assessments should be interpreted with caution; current laboratory 2 105 2.86 13.33 29.52 47.62 6.67 0.42 Controversial
tests require improvement in terms of sensitivity and specificity. 4 . 9 . d 3 105 0 13.33 25.71 54.29 6.67 0.54 Controversial
Adrenal insufficiency should be assessed: never; patients should be systematically
substituted during tapering irrespective of any test. 4 . 9 . e 1 101 17.82 56.44 22.77 2.97 0 -0.89 Negative
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Adrenal insufficiency should be assessed: never; patients should be substituted during
tapering only according to signs/symptoms. 4 . 9 . f 1 101 20.79 50.5 19.8 7.92 0.99 -0.82 Negative
Adrenal insufficiency is insufficiently assessed or under-recognized. 4 . 11 . a 1 101 0.99 1.98 15.84 54.46 26.73 1.04 Positive
Steroid withdrawal syndrome (symptoms of glucocorticoid deficiency in the setting of a 1 101 0 2.97 38.61 51.49 6.93 0.62 Controversial
proven normal hypothalamic-pituitary-adrenal axis) occurs more often than adrenal 2 105 0 10.48 31.43 50.48 7.62 0.55 Controversial
insufficiency. 4 . 11 . b 3 105 0 7.62 29.52 57.14 5.71 0.61 Controversial
1 101 0.99 15.84 24.75 53.47 4.95 0.46 Controversial
Administration of exogenous glucocorticoids even in small doses for only a few days leads 2 105 1.9 24.76 22.86 44.76 5.71 0.28 Controversial
to a measurable suppression of the hypothalamic-pituitary-adrenal axis. 4 . 11 . c 3 105 0.95 17.14 28.57 49.52 3.81 0.38 Controversial
1 101 0.99 13.86 29.7 49.5 5.94 0.46 Controversial
OCS treatment may not suppress the hypothalamic-pituitary-adrenal axis at all, or it 2 105 1.9 10.48 33.33 45.71 8.57 0.49 Controversial
may cause central suppression and adrenal gland atrophy of varying degrees. 4 . 11 . d 3 105 0.95 6.67 34.29 52.38 5.71 0.55 Controversial
1 101 2.97 31.68 18.81 43.56 2.97 0.12 Controversial
2 105 9.52 32.38 19.05 35.24 3.81 -0.09 Controversial
A correct OCS tapering regime does not require frequent assessments of adrenal insufficiency. 4 . 12 . a 3 105 4.76 27.62 20 43.81 3.81 0.14 Controversial
Reduce the dose of glucocorticoid replacement to the minimum dose possible. This 1 101 2.97 19.8 49.5 26.73 0.99 0.03 Controversial
should be judged on hydrocortisone day curves (if on hydrocortisone), or prednisolone day 2 105 3.81 22.86 51.43 20.95 0.95 -0.08 Controversial
curves/8- hour prednisolone levels. 4 . 12 . b 3 105 1.9 25.71 48.57 22.86 0.95 -0.05 Controversial
1 101 0 11.88 24.75 59.41 3.96 0.55 Controversial
If systemic effects (e.g. arthritis pain) occur during OCS tapering, patients are advised to 2 105 0.95 10.48 22.86 59.05 6.67 0.6 Controversial
slow down the tapering pace because the complaints will disappear after some time. 4 . 12 . c 3 105 0 10.48 24.76 61.9 2.86 0.57 Controversial
If adrenal insufficiency occurs during tapering, first increase OCS, and then later re-
attempt tapering at a slower pace. 4 . 12 . d 1 101 2.97 13.86 19.8 57.43 5.94 0.5 Controversial
If adrenal insufficiency occurs during tapering, first increase OCS, and then later re-
attempt tapering at a slower pace. 4 . 12 . d 2 105 2.86 9.52 15.24 65.71 6.67 0.64 Positive
1 101 0 19.8 23.76 55.45 0.99 0.38 Controversial
When symptoms occur, stop further tapering until they resolve (this can take 2 105 1.9 23.81 16.19 56.19 1.9 0.32 Controversial
weeks/months), and then continue. 4 . 12 . e 3 105 0.95 15.24 24.76 55.24 3.81 0.46 Controversial
1 101 4.95 41.58 22.77 28.71 1.98 -0.19 Controversial
2 105 8.57 29.52 26.67 33.33 1.9 -0.1 Controversial
An undetectable eosinophil count may be a sign of glucocorticoid excess. 4 . 13 . a 3 105 6.67 31.43 22.86 38.1 0.95 -0.05 Controversial
1 101 0.99 21.78 32.67 37.62 6.93 0.28 Controversial
2 105 0 24.76 29.52 37.14 8.57 0.3 Controversial
The interpretation of short Synacthen test results should take into account the effect of inhaled glucocorticoids. 4 . 13 . b 3 105 0 19.05 35.24 40.95 4.76 0.31 Controversial
1 101 2.97 14.85 63.37 18.81 0 -0.02 Controversial
Patients who fail their first short Synacthen test with a 30-min cortisol of <350 nmol/L 2 105 0.95 12.38 60.95 22.86 2.86 0.14 Controversial
or 12 g/dL, should be counselled that there is a 50% chance of lifelong replacement therapy.  4 . 13 . c 3 105 0.95 14.29 60 23.81 0.95 0.1 Controversial
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1 101 2.97 15.84 62.38 17.82 0.99 -0.02 Controversial
Patients with a subsequent morning cortisol of <200 nmol/L should be informed that 2 105 0.95 17.14 64.76 15.24 1.9 0 Controversial
there is a >90% chance that they will need lifelong steroids. 4 . 13 . d 3 105 1.9 11.43 60.95 24.76 0.95 0.11 Controversial
Patient-physician shared decision-making for OCS tapering should be a systematic practice. 5 . 1 . a 1 101 0 1.98 4.95 52.48 40.59 1.32 Positive
1 101 8.91 39.6 8.91 38.61 3.96 -0.11 Controversial
2 105 13.33 39.05 9.52 32.38 5.71 -0.22 Controversial
In most cases, the decision to taper OCS treatment is not shared, but taken alone by the clinician. 5 . 1 . b 3 105 6.67 50.48 11.43 26.67 4.76 -0.28 Controversial
1 101 1.98 25.74 10.89 38.61 22.77 0.54 Controversial
2 105 2.86 31.43 13.33 35.24 17.14 0.32 Controversial
The self-management of OCS treatments should be discouraged. 5 . 1 . c 3 105 1.9 33.33 14.29 40.95 9.52 0.23 Controversial
The self-management of OCS tapering should be limited to patients with a good level of comprehension. 5 . 1 . d 1 101 1.98 14.85 11.88 57.43 13.86 0.66 Positive
Patient-physician shared decision-making for OCS tapering is important because: it
educates the patient on the benefits/risks associated with OCS use. 5 . 2 . a 1 101 0 0 0.99 58.42 40.59 1.4 Positive
Patient-physician shared decision-making for OCS tapering is important because: it allows
the patients to understand the purpose of OCS tapering. 5 . 2 . b 1 101 0 0 0 66.34 33.66 1.34 Positive
Patient-physician shared decision-making for OCS tapering is important because: it
provides necessary support and guidance to the patient. 5 . 2 . c 1 101 0 0 3.96 65.35 30.69 1.27 Positive
Patient-physician shared decision-making for OCS tapering is important because: it can
increase the chances of success; improve outcomes. 5 . 2 . d 1 101 0 1.98 1.98 61.39 34.65 1.29 Positive
Patient-physician shared decision-making for OCS tapering is important because:
ambivalent attitudes towards tapering are frequent. 5 . 2 . e 1 101 0 6.93 13.86 59.41 19.8 0.92 Positive
Patient-physician shared decision-making for OCS tapering is important because: "aches and pains" during 
OCS withdrawal can occur, and planning how to manage them is likely to improve withdrawal progress. 5 . 2 . f 1 101 0.99 0.99 3.96 62.38 31.68 1.23 Positive
Patient-physician shared decision-making for OCS tapering is important because: patient
engagement/empowerment in the process can optimize the outcome. 5 . 2 . g 1 101 0 0 1.98 62.38 35.64 1.34 Positive
Patient-physician shared decision-making for OCS tapering is important because: patients
are often expected to self-medicate at home. 5 . 2 . h 1 101 1.98 4.95 15.84 63.37 13.86 0.82 Positive
Patient-physician shared decision-making should include: a decision aid including full
disclosure of short- and long-term exacerbation/adverse events profile. 5 . 3 . a 1 101 0 1.98 11.88 66.34 19.8 1.04 Positive
Patient-physician shared decision-making should include: patient education on the
benefits/risks associated with OCS use. 5 . 3 . b 1 101 0 0 0 65.35 34.65 1.35 Positive
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Patient-physician shared decision-making should include: the benefits/risks associated
with OCS tapering and why it is important. 5 . 3 . c 1 101 0 0 0 56.44 43.56 1.44 Positive
Patient-physician shared decision-making should include: the dangers of abrupt tapering
/OCS discontinuation. 5 . 3 . d 1 101 0 0 0 56.44 43.56 1.44 Positive
Patient-physician shared decision-making should include: the patient's thoughts
(concerns, fears, hopes, expectations) and preferences. 5 . 3 . e 1 101 0 0 3.96 60.4 35.64 1.32 Positive
Patient-physician shared decision-making should include: symptoms that may occur due
to weaning, how to recognize and manage them (including adrenal insufficiency). 5 . 3 . f 1 101 0 0.99 0.99 60.4 37.62 1.35 Positive
Patient-physician shared decision-making should include: multidisciplinary work (for
example, collaboration between respiratory, endocrinology, and rheumatology experts). 5 . 3 . g 1 101 0.99 3.96 12.87 49.5 32.67 1.09 Positive
Patient-physician shared decision-making should include: a joint evaluation of the
patient's global health status and/or quality of life. 5 . 3 . h 1 101 0 3.96 11.88 66.34 17.82 0.98 Positive
Patient-physician shared decision-making should include: using biomarkers for 1 101 0.99 10.89 26.73 53.47 7.92 0.56 Controversial
monitoring and individualization of the action plan. 5 . 3 . i 2 105 0.95 12.38 16.19 60.95 9.52 0.66 Positive
Patient-physician shared decision-making should include: steroid-sparing strategies and their benefits/risks. 5 . 3 . j 1 101 0 0.99 5.94 61.39 31.68 1.24 Positive
Patient-physician shared decision-making should include: clear, agreed-upon
protocols/action plan on how tapering will be carried out and what to expect. 5 . 3 . k 1 101 0 0.99 4.95 62.38 31.68 1.25 Positive
Patient-physician shared decision-making should include: a warning regarding the
consequences of not following the action plan. 5 . 3 . l 1 101 0.99 2.97 7.92 70.3 17.82 1.01 Positive
Patient-physician shared decision-making should include: a means of contacting the
doctor/team so the patient can reach out and get support. 5 . 3 . m 1 101 0 0.99 3.96 59.41 35.64 1.3 Positive
Patient-physician shared decision-making should include: discussion with both patients
and their families/caregivers. 5 . 3 . n 1 101 0 1.98 11.88 59.41 26.73 1.11 Positive
Advice for OCS self-managers: if possible, do not opt for regular OCS use. 5 . 4 . a 1 101 0 1.98 7.92 51.49 38.61 1.27 Positive
Advice for OCS self-managers: the lowest active dose of OCS for the shortest duration is preferable. 5 . 4 . b 1 101 0 0 1.98 53.47 44.55 1.43 Positive
Advice for OCS self-managers: closely monitor symptoms while tapering, including those
of adrenal insufficiency. 5 . 4 . c 1 101 0 0 5.94 59.41 34.65 1.29 Positive
Advice for OCS self-managers: help the process of OCS tapering by overcoming minor discomfort related to it. 5 . 4 . d 1 101 0.99 0 3.96 67.33 27.72 1.21 Positive
Advice for OCS self-managers: respect your doctor's recommendations in as much as
possible, and contact him/her (or team) when there is a problem. 5 . 4 . e 1 101 0 0.99 3.96 63.37 31.68 1.26 Positive
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Advice for OCS self-managers: increase the OCS dose to the previous dose if a weaning
step causes (intolerable) symptoms. 5 . 4 . f 1 101 0 3.96 10.89 54.46 30.69 1.12 Positive
1 101 0.99 10.89 22.77 44.55 20.79 0.73 Controversial
Advice for OCS self-managers: never use a dose lower than the agreed-up threshold 2 105 4.76 23.81 29.52 35.24 6.67 0.15 Controversial
(e.g. 7.5 mg) without substitution. 5 . 4 . g 3 105 0.95 33.33 23.81 37.14 4.76 0.11 Controversial
Advice for OCS self-managers: always make dosage changes under medical supervision. 5 . 4 . h 1 101 0 10.89 15.84 52.48 20.79 0.83 Positive
Physicians should drive the decision-making when it comes to OCS tapering. 5 . 5 . a 1 101 0 8.91 12.87 59.41 18.81 0.88 Positive
1 101 1.98 10.89 21.78 56.44 8.91 0.59 Controversial
2 105 0.95 27.62 17.14 48.57 5.71 0.3 Controversial
Physicians should limit prescriptions to ensure that tapering is occurring. 5 . 5 . b 3 105 1.9 19.05 21.9 56.19 0.95 0.35 Controversial
1 101 1.98 23.76 26.73 29.7 17.82 0.38 Controversial
2 105 2.86 30.48 14.29 41.9 10.48 0.27 Controversial
The self-management of OCS treatments should be discouraged. 5 . 5 . c 3 105 1.9 39.05 12.38 39.05 7.62 0.11 Controversial
1 101 4.95 41.58 10.89 35.64 6.93 -0.02 Controversial
2 105 3.81 47.62 15.24 30.48 2.86 -0.19 Controversial
Forewarning patients of "aches and pains" during OCS withdrawal is likely to impede withdrawal progress. 5 . 5 . d 3 105 2.86 49.52 11.43 33.33 2.86 -0.16 Controversial
1 101 0 9.9 24.75 55.45 9.9 0.65 Controversial
2 105 0.95 7.62 25.71 59.05 6.67 0.63 Controversial
When OCS tapering decisions are not taken mutually, this can lead to medical malpractice and litigation. 5 . 5 . e 3 105 0 8.57 27.62 58.1 5.71 0.61 Controversial
1 101 3.96 24.75 35.64 31.68 3.96 0.07 Controversial
2 105 9.52 41.9 15.24 32.38 0.95 -0.27 Controversial
In some cases, you might need to have a consent form signed before patients start OCS treatment. 5 . 5 . f 3 105 6.67 36.19 23.81 30.48 2.86 -0.13 Controversial
Many times, patients feel their safety depends on OCS and it takes a lot of effort to convince them to taper. 5 . 5 . g 1 101 0 9.9 19.8 55.45 14.85 0.75 Positive
The majority of patients want to reduce their OCS use and will actively participate in doing so. 5 . 5 . h 1 101 0 2.97 10.89 62.38 23.76 1.07 Positive
OCS tapering can be successful even if the patient doesn't think it will work. 5 . 5 . i 1 101 0.99 4.95 16.83 62.38 14.85 0.85 Positive
1 101 4.95 36.63 26.73 25.74 5.94 -0.09 Controversial
It is better to allow patients to control their own prednisolone doses to control symptoms 2 105 4.76 40.95 29.52 23.81 0.95 -0.25 Controversial
than to give high dose bursts for exacerbations. 5 . 5 . j 3 105 2.86 45.71 26.67 22.86 1.9 -0.25 Controversial
1 101 0 13.86 35.64 43.56 6.93 0.44 Controversial
The patient generally has full confidence in his/her doctor and experiences tapering as a 2 105 0 10.48 35.24 52.38 1.9 0.46 Controversial
success on his/her illness. 5 . 5 . k 3 105 0 14.29 30.48 48.57 6.67 0.48 Controversial
1 101 0.99 12.87 30.69 46.53 8.91 0.5 Controversial
The patient is usually the major player and follows an action plan with an easy contact 2 105 0.95 10.48 26.67 56.19 5.71 0.55 Controversial
with the multidisciplinary team.   5 . 5 . l 3 105 1.9 15.24 20.95 57.14 4.76 0.48 Controversial
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Physicians should be trained on how to coach patients during the tapering process. 5 . 5 . m 1 101 0 0 8.91 72.28 18.81 1.1 Positive
Patients should be educated with standard material (generated and endorsed e.g. by ERS) about the OCS therapy. 5 . 5 . n 1 101 0 0.99 6.93 75.25 16.83 1.08 Positive
1 101 1.98 20.79 15.84 51.49 9.9 0.47 Controversial
Shared decision-making is made difficult by the level of individualization and adaptation 2 105 1.9 32.38 22.86 40 2.86 0.1 Controversial
required during OCS tapering. 5 . 5 . o 3 105 0.95 38.1 20.95 38.1 1.9 0.02 Controversial
Shared decision-making is dependent on the willingness and ability of both sides to interact. 5 . 5 . p 1 101 0 0 3.96 69.31 26.73 1.23 Positive
Patients are suffering a lot and a strong patient-doctor relationship is required to achieve
a safe, optimum outcome from OCS tapering. 5 . 5 . q 1 101 0.99 0 13.86 53.47 31.68 1.15 Positive
All OCS-treated asthma patients should be referred to an expert center able to propose
multidisciplinary assessment and access to innovations. 6 . 1 . a 1 101 0 1.98 5.94 38.61 53.47 1.44 Positive
Maintenance OCS for severe asthma should only be considered after evaluation by a
severe asthma specialist (the definition of this specialist may vary from region to region). 6 . 1 . b 1 101 0 2.97 4.95 32.67 59.41 1.49 Positive
The respiratory physician treating severe asthma patients must assess for adrenal insufficiency. 6 . 1 . c 1 101 0.99 6.93 13.86 49.5 28.71 0.98 Positive
Adrenal insufficiency management in patients with severe asthma should involve an
endocrinologist/multidisciplinary approach. 6 . 1 . d 1 101 0 3.96 23.76 38.61 33.66 1.02 Positive
Primary care physicians prescribing more than three courses of OCS to a patient with
asthma in 1 year should consider a referral to a specialist. 6 . 2 . a 1 101 0 0.99 0 27.72 71.29 1.69 Positive
The primary care physician should be part of the multidisciplinary team. 6 . 2 . b 1 101 0 3.96 16.83 55.45 23.76 0.99 Positive
1 101 6.93 28.71 6.93 36.63 20.79 0.36 Controversial
2 105 10.48 28.57 8.57 33.33 19.05 0.22 Controversial
OCS use in asthma should also be discouraged at the primary care level. 6 . 2 . c 3 105 7.62 29.52 9.52 34.29 19.05 0.28 Controversial
The following is an important subject of future research: improving the delivery of asthma care. 6 . 3 . a 1 101 0 0.99 5.94 54.46 38.61 1.31 Positive
The following is an important subject of future research: integration and dissemination of
how to use predictive biomarkers in clinical practice. 6 . 3 . b 1 101 0 2.97 8.91 57.43 30.69 1.16 Positive
The following is an important subject of future research: improving the use of biological treatments in asthma. 6 . 3 . c 1 101 0 0 4.95 38.61 56.44 1.51 Positive
The following is an important subject of future research: while striving to obtain a
balance between over and under-treatment with OCS, patients often experience adverse
quality of life. How best to manage this requires future research. 6 . 3 . d 1 101 0 0 19.8 55.45 24.75 1.05 Positive
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The following is an important subject of future research: whether hydrocortisone
supplementation is less harmful than prednisone should be established. 6 . 3 . e 1 101 0.99 2.97 15.84 50.5 29.7 1.05 Positive
The following is an important subject of future research: The impact of shared decision-
making on important outcomes. 6 . 3 . f 1 101 0 0.99 20.79 52.48 25.74 1.03 Positive
The following is an important subject of future research: OCS tapering regime algorithms and optimization. 6 . 3 . g 1 101 0.99 0.99 5.94 50.5 41.58 1.31 Positive
The following is an important subject of future research: real-life, cost-
benefit/effectiveness evaluations for steroid-sparing strategies taking into account side-
effects and comorbidities, quality of life, and the societal costs of maintenance OCS. 6 . 3 . h 1 101 0 0 6.93 40.59 52.48 1.46 Positive
The following is an important subject of future research: direct comparisons between
biologicals, especially anti-IL-5. 6 . 3 . i 1 101 0.99 0.99 10.89 38.61 48.51 1.33 Positive
The following is an important subject of future research: strategic ways to reduce OCS use
for the overall at-risk populations. 6 . 3 . j 1 101 0 0.99 2.97 58.42 37.62 1.33 Positive
The following is an important subject of future research: methods for determining OCS starting doses. 6 . 3 . k 1 101 0 7.92 17.82 55.45 18.81 0.85 Positive
The following is an important subject of future research: the role of the endocrinologist
and when referral should occur. 6 . 3 . l 1 101 0 4.95 11.88 64.36 18.81 0.97 Positive
The following is an important subject of future research: improving the assessment of adrenal insufficiency. 6 . 3 . m 1 101 0.99 0 7.92 54.46 36.63 1.26 Positive
1 101 0.99 9.9 22.77 47.52 18.81 0.73 Controversial
The following is an important subject of future research: the efficacy of internet-provided 2 105 0 13.33 22.86 50.48 13.33 0.64 Controversial
algorithms for delivering symptom-driven OCS tapering guidance to asthma patients. 6 . 3 . n 3 105 0 11.43 20.95 59.05 8.57 0.65 Controversial
The following is an important subject of future research: how should OCS tapering be
addressed in countries where there is limited access to biological treatments? 6 . 3 . o 1 101 0 2.97 8.91 58.42 29.7 1.15 Positive
The following is an important subject of future research: what aspect/phenotype of 
asthma is being treated by OCS that the currently available biological therapies are not treating? 6 . 3 . p 1 101 0 0.99 7.92 42.57 48.51 1.39 Positive
The following is an important subject of future research: in the context of successful OCS 
weaning subsequent to the initiation of a biological, what kind of follow-up should be proposed? 6 . 3 . q 1 101 0 1.98 15.84 56.44 25.74 1.06 Positive
ABPA = allergic bronchopulmonary aspergillosis; ACOS = Asthma-COPD overlap syndrome; ACQ = Asthma Control Questionnaire; ACT = Asthma Control Test; BAL =  bronchoalveolar lavage fluid; COPD = chronic 
obstructive pulmonary disease; DDAVP = desmopressin; EGPA = eosinophilic granulomatosis with polyangiitis; ERS = European Respiratory Society; FRAX = Fracture Risk Assessment Tool; GERD = gastroesophageal reflux 
disease; GINA = Global Initiative for Asthma; HbA1c = hemoglobin A1c; ICS = inhaled corticosteroid; IL =  interleukin; MCID = minimal clinically important difference; OCS = oral corticosteroid; PDGF-D = platelet-derived 
growth factor D
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The OCS Tapering Delphi Expert Panel
(Alphabetical order)
• Al-Ahmad, Mona
– Microbiology Department, Faculty of Medicine, Kuwait University, Kuwait
• Babu, K Suresh
– Queen Alexandra Hospital, Portsmouth, Hampshire, PO6 3LY, United Kingdom
• Bakakos, Petros
– 11 Kononos St, Athens, Attiki, 11634, Greece
• Ball, Stephen
– Manchester University Foundation Trust, Endocrinology Department, Oxford 
Road, Manchester, M13 9WL, United Kingdom
• Bel, Elisabeth
– Department of Pulmonology, F5-168, Amsterdam UMC, Univ. of Amsterdam, 
Meibergdreef 9, Amsterdam, 1105AZ, Netherlands
• Bjermer, Leif
– Department of Lung and Allergology, Skane University Hospital, Lund, 22185, 
Sweden
• Blanc, François-Xavier
– Nantes University, Nantes, 44093, France
• Blasi, Francesco
– Internal Medicine Department, Respiratory Unit and Adult Cystic Fibrosis Center, 
Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milano, and 
Department of Pathophysiology and Transplantation, Università degli Studi di 
Milano, Italy
• Bourdin, Arnaud
– Department of Respiratory Diseases, University of Montpellier, CHU 
Montpellier, Montpellier, France
• Brown, Thomas
– Portsmouth Hospitals NHS Trust, Queen Alexandra Hospital, Southwick Hill Road, 
Cosham, Portsmouth, Hampshire, PO63LY, United Kingdom
• Brussino, Luisa
– Department of Medical Science, University of Torino-Allergy and 
Immunology Unit, Mauriziano Hospital, C.so Re Umberto 109, Torino, 
10100, Italy
• Burhan, Hassan
– Royal Liverpool University Hospital, Prescot Street, Link 6Z, Royal Liverpool 
University Hospital, Prescot Street, Liverpool, L7 8XP, United Kingdom
• Calvert, James
– North Bristol NHS Trust, Westbury on Trym, Bristol, Avon, BS10 5NB, United 
Kingdom
• Caminati, Marco
– Department of Medicine, University of Verona & Asthma Center and Allergy Unit, 
Verona University Hospital, Verona, Italy
• Campos Cerda, Ricardo
– Centro de Atención de Enfermedades Cardiopulmonares, 880 Garibaldi St, Office 9, 
1st Floor, Guadalajara, Jalisco, 44200, Mexico
• Canonica, Giorgio Walter
– Personalised Medicine, Asthma and Allergy Center, Humanitas Research 
Hospital, Milan, Italy
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• Caruso, Cristiano
– Fondazione Policlinico Universitario A. Gemelli IRCSS, Rome, Italy
• Cataldo, Didier
– University of Liege (GIGA-research center) and CHU of Liege, Tower of 
Pathology (B23), Hippocrates Avenue 13, Liege, 4000, Belgium
• Chanez, Pascal
– Department of Respiratory Diseases, AP-HM, INSERM, INRA, C2VN Aix 
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